

Financial news for REGN dated on 2020-06-05: Friday's Market Minute: Nasdaq's Top Performers: TSLA, REGN, PYPL

Financial news for REGN dated on 2020-06-05: Regeneron CEO To Join Meg Tirrell On Special CNBC COVID-19 Program At 7 p.m. EDT

Financial news for REGN dated on 2020-06-03: Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics

Financial news for REGN dated on 2020-06-03: Regeneron Shares Quiet Following Headline US PTO Upheld A Fifth Patent From Kymab Covering Human Antibodies, Rejected Request By Regeneron

Financial news for REGN dated on 2020-06-03: The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study

Financial news for REGN dated on 2020-06-02: Sanofi's CEO On Cancer Research, Coronavirus Vaccine Progress

Financial news for REGN dated on 2020-06-02: Inovio Analyst Watches Coronavirus Play 'From The Sidelines'

Financial news for REGN dated on 2020-06-01: Regeneron And Intellia Therapeutics Expand Collaboration To Develop CRISPR/Cas9-Based Treatments; Intellia To Receive Upfront Payment Of \$70M, And Regeneron Will Make An Additional Equity Investment In Intellia Of \$30M At \$32.42 Per Share

Financial news for REGN dated on 2020-05-29: Stocks That Hit 52-Week Highs On Friday

Financial news for REGN dated on 2020-05-29: Sanofi Reports Libtayo Longer-Term Results In Advanced Cutaneous Squamous Cell Carcinoma Presented At ASCO Show Durable Responses

Financial news for REGN dated on 2020-05-28: Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.

Financial news for REGN dated on 2020-05-27: CFRA Maintains Hold on Regeneron Pharmaceuticals, Lowers Price Target to \$549

Financial news for REGN dated on 2020-05-27: SVB Leerink Reiterates Outperform on Regeneron Pharmaceuticals, Raises Price Target to \$625

Financial news for REGN dated on 2020-05-27: The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Financial news for REGN dated on 2020-05-27: 11.8M Share Secondary Offering of Regeneron Common Stock Held by Sanofi Priced \$515/Share

Financial news for REGN dated on 2020-05-26: Sanofi: FDA approves Dupixent(r) (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis

Financial news for REGN dated on 2020-05-26: Benzinga's Top Upgrades, Downgrades For May 26, 2020

Financial news for REGN dated on 2020-05-26: Wells Fargo Upgrades Regeneron Pharmaceuticals to Overweight, Announces \$734 Price Target

Financial news for REGN dated on 2020-05-25: Sanofi Currently Holds ~20.6% of Regeneron's Capital

Financial news for REGN dated on 2020-05-25: Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and \$5B Stock Repurchase

Financial news for REGN dated on 2020-05-24: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for REGN dated on 2020-05-20: Short Sellers Challenge Sorrento's Announcement Of 100% Coronavirus Inhibition: 'Manipulative At The Worst Time'

Financial news for REGN dated on 2020-05-20: Shares of several healthcare companies are trading higher in sympathy with the overall market amid strength in oil, strong earnings from Lowe's and optimism towards a US economic rebound.

Financial news for REGN dated on 2020-05-20: Clinical Research and Development Efforts Booming in Midst of COVID-19 Health Crisis

Financial news for REGN dated on 2020-05-20: Checkpoint Therapeutics CEO On Tapping Into A \$25 Billion Cancer Treatment Market

Financial news for REGN dated on 2020-05-19: Moderna Short Sellers Take \$450M Hit Following Coronavirus Vaccine Data

Financial news for REGN dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for REGN dated on 2020-05-18: Stocks That Hit 52-Week Highs On Monday

Financial news for REGN dated on 2020-05-14: The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger

Financial news for REGN dated on 2020-05-13: Regeneron Highlights Upcoming Presentations At ASCO

Financial news for REGN dated on 2020-05-11: Regeneron And Colorado Center For Personalized Medicine Announce Human Genetics Research Collaboration

Financial news for REGN dated on 2020-05-06: Baird Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target of \$510

Financial news for REGN dated on 2020-05-06: BMO Capital Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to \$525

Financial news for REGN dated on 2020-05-06: Regeneron shares are trading lower. Not currently seeing company-specific news.

Financial news for REGN dated on 2020-05-06: Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to \$555

Financial news for REGN dated on 2020-05-06: Credit Suisse Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to \$605

Financial news for REGN dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for REGN dated on 2020-05-06: 10 Biggest Price Target Changes For Wednesday

Financial news for REGN dated on 2020-05-06: SVB Leerink Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to \$622

Financial news for REGN dated on 2020-05-05: Stocks That Hit 52-Week Highs On Tuesday

Financial news for REGN dated on 2020-05-05: Regeneron CEO Sees Possibility An Antibody Cocktail Therapy Could Be Available To Treat Coronavirus By End Of Summer Or Fall

Financial news for REGN dated on 2020-05-05: From Conference Call: Regeneron EO Says Encouraged by Rebound in Demand for Drugs in Recent Weeks Amid Covid-19 Outbreak

Financial news for REGN dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for REGN dated on 2020-05-05: Regeneron Pharmaceuticals shares are trading higher after the company announced its Libtayo PD-1 inhibitor showed clinically meaningful and durable responses in second-line advanced basal cell carcinoma. The company also reported better-than-expected Q1 EPS results.

Financial news for REGN dated on 2020-05-05: Regeneron Pharmaceuticals Q1 Adj. EPS \$6.600 Beats \$6.200 Estimate, Sales \$1.830B Miss \$1.850B Estimate

Financial news for REGN dated on 2020-05-05: Regeneron and Sanofi Announce Libtayo Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma

Financial news for REGN dated on 2020-05-05: Earnings Scheduled For May 5, 2020

Financial news for REGN dated on 2020-05-03: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

Financial news for REGN dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for REGN dated on 2020-04-28: Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to \$575

Financial news for REGN dated on 2020-04-28: 10 Biggest Price Target Changes For Tuesday

Financial news for REGN dated on 2020-04-28: Citigroup Downgrades Regeneron Pharmaceuticals to Neutral, Raises Price Target to \$575

Financial news for REGN dated on 2020-04-27: Why Regeneron's Stock Is Trading Lower Today

Financial news for REGN dated on 2020-04-27: Regeneron shares are trading lower. The company's trial of arthritis drug Kevzara with Sanofi showed potential for treating the sickest coronavirus patients but showed less benefit in patients with less-advanced disease.

Financial news for REGN dated on 2020-04-27: Regeneron's Phase 3 Trial of Libtayo as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival

Financial news for REGN dated on 2020-04-27: Sanofi and Regeneron Say its Phase 2/3 Adaptive-Designed Trial of Kevzara in Hospitalized Coronavirus Patients Met its Primary Endpoint

Financial news for REGN dated on 2020-04-26: 7 Best-Performing Stocks Of 2020: Buy, Sell Or Hold?

Financial news for REGN dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for REGN dated on 2020-04-23: Shares of several healthcare companies are trading higher. Movement appears market-related as equities gain amid a rebound in oil prices.

Financial news for REGN dated on 2020-04-21: Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.

Financial news for REGN dated on 2020-04-21: The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives

Financial news for REGN dated on 2020-04-17: Stocks That Hit 52-Week Highs On Friday

Financial news for REGN dated on 2020-04-17: Benzinga's Top Upgrades, Downgrades For April 17, 2020

Financial news for REGN dated on 2020-04-17: Regeneron Pharmaceuticals shares are trading higher after Benchmark upgraded the stock from Hold to Buy.

Financial news for REGN dated on 2020-04-17: The Daily Biotech Pulse: Moderna Secures \$483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement

Financial news for REGN dated on 2020-04-17: Benchmark Upgrades Regeneron Pharmaceuticals to Buy

Financial news for REGN dated on 2020-04-16: Regeneron Shares Tick Higher Following Co. Tweet 'COVID19 program update: We have moved our top SARS-CoV-2-neutralizing antibodies into preclinical-, clinical-scale cell production lines, remain on track to have supply available for studies in Jun.'

Financial news for REGN dated on 2020-04-16: Regeneron Pharmaceuticals shares are trading higher after the company announced the FDA has accepted for priority review a biologics license application for REGN-EB3 to treat Ebola.

Financial news for REGN dated on 2020-04-16: The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant

Financial news for REGN dated on 2020-04-16: Regeneron Reports FDA Accepted For Priority Review New Biologics License Application For REGN-EB3, A Triple Antibody Cocktail Treatment For Ebola; FDA Target Action Date Set For Oct. 25, 2020

Financial news for REGN dated on 2020-04-15: Every Member Of Trump's 'Great American Economic Revival' Industry Groups

Financial news for REGN dated on 2020-04-15: Morgan Stanley Maintains Equal-Weight on

Regeneron Pharmaceuticals, Lowers Price Target to \$409

Financial news for REGN dated on 2020-04-15: Stocks That Hit 52-Week Highs On Wednesday

Financial news for REGN dated on 2020-04-15: JP Morgan Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to \$429

Financial news for REGN dated on 2020-04-15: The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US

Financial news for REGN dated on 2020-04-14: Stocks That Hit 52-Week Highs On Tuesday

Financial news for REGN dated on 2020-04-14: The Daily Biotech Pulse: Amarin Reports Strong Q1 Vascepa Sales, BeiGene Aces Late-Stage Lung Cancer Study, Glaxo, Sanofi Strike COVID-19 Vaccine Partnership

Financial news for REGN dated on 2020-04-13: Stocks That Hit 52-Week Highs On Monday

Financial news for REGN dated on 2020-04-08: Sanofi CEO Talks Coronavirus Vaccine Development, Potential Treatment

Financial news for REGN dated on 2020-04-08: Benzinga's Top Upgrades, Downgrades For April 8, 2020

Financial news for REGN dated on 2020-04-08: Benchmark Initiates Coverage On Regeneron Pharmaceuticals with Hold Rating

Financial news for REGN dated on 2020-04-08: Regeneron And Zai Lab Announce Regional Strategic Collaboration For REGN1979 (CD20xCD3 Bispecific Antibody); Regeneron To Receive \$30M Upfront, Eligible To Receive Up To \$160M In Additional Milestones

Financial news for REGN dated on 2020-04-07: SVB Leerink Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to \$604

Financial news for REGN dated on 2020-04-07: Jim Cramer, On CNBC's 'Squawk On The Street,' Says He Is More Bullish On Regeneron Than Gilead

Financial news for REGN dated on 2020-04-07: The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation

Financial news for REGN dated on 2020-04-06: Trump Says Spoke With Pharmaceutical Companies; Says 10 Different Therapeutic Agents Are In Active Trials, Says Will Be 'Fairly Quick Process' And Says A Second Company Was Approved To Start Vaccine Trials

Financial news for REGN dated on 2020-04-06: STAT News Reporter Says CEOs Of Amgen, Genentech, Gilead And Regeneron Were Involved In Call With Trump

Financial news for REGN dated on 2020-04-06: Sanofi Finalizes Praluent Restructuring With Regeneron

Financial news for REGN dated on 2020-04-06: 'There are four main antibody programs underway in U.S. by Lilly, Regeneron, Vir, and Amgen. Regeneron may be furthest along and have the best chance of doing this at the scale required...' -Weekend Tweet From Former FDA Commish Gottlieb

Financial news for REGN dated on 2020-04-06: Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to \$435

Financial news for REGN dated on 2020-04-03: Regeneron's Coronavirus Program May Have Results At End Of April

Financial news for REGN dated on 2020-04-03: The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO

Financial news for REGN dated on 2020-04-03: Sanofi Reports Dupixent Phase 3 Data Show Significant Improvement in Severe Atopic Dermatitis for Children Aged 6 to 11 Years

Financial news for REGN dated on 2020-03-30: Regeneron Highlights Results From Phase 3 Study Of Evinacumab In Patients With Severe Inherited Form Of High Cholesterol Presented At American College of Cardiology's Annual Scientific Session

Financial news for REGN dated on 2020-03-30: Regeneron and Sanofi shares are trading higher after the companies announced the dosing of the first patient in their trial of Kevzara for coronavirus.

Financial news for REGN dated on 2020-03-30: Sanofi Reports First Patient Outside

U.S. Treated in Global Kevzara Clinical Trial Program for Patients with Severe COVID-19

Financial news for REGN dated on 2020-03-29: Ex-FDA Chief Gottlieb Expects Coronavirus Therapeutic Option By Summer

Financial news for REGN dated on 2020-03-27: 10 Stocks To Buy With Low Debt And High Liquidity

Financial news for REGN dated on 2020-03-25: Zoom Video, Teladoc Lead The Coronavirus Short Squeeze Candidates

Financial news for REGN dated on 2020-03-24: Chloroquine, Hydroxychloroquine And Coronavirus: What You Should Know

Financial news for REGN dated on 2020-03-23: Shares of several healthcare companies are trading higher the Fed announced actions to support the U.S. economy. The Fed will do open-ended treasury, mortgage-backed securities and will buy \$375 billion in treasury this week.

Financial news for REGN dated on 2020-03-20: The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company

Financial news for REGN dated on 2020-03-19: Trump Mentions Regeneron At Coronavirus Task Force Presser, Discusses Gilead As Near Approval Via FDA, Then Highlights Regeneron Trial

Financial news for REGN dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for REGN dated on 2020-03-18: 130 Biggest Movers From Yesterday

Financial news for REGN dated on 2020-03-17: 94 Stocks Moving In Tuesday's Mid-Day Session

Financial news for REGN dated on 2020-03-17: Regeneron Pharmaceuticals shares are trading higher after the company said its coronavirus antibody program could enter the clinics as early as early summer, with the potential to enter human clinical trials by Summer.

Financial news for REGN dated on 2020-03-17: Hearing Regeneron CEO Will Be On Jim Cramer's 'Mad Money' Tonight

Financial news for REGN dated on 2020-03-17: Regeneron Working To Rush 'Cocktail' COVID-19 Antibody To Clinics At Start Of Summer

Financial news for REGN dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for REGN dated on 2020-03-17: Regeneron Announces 'Important Advances' In Coronavirus Antibody Program; Says Plans To 'initiate large-scale manufacturing by mid-April with antibody cocktail therapy' With Potential To Enter Human Clinical Trials By Summer

Financial news for REGN dated on 2020-03-16: Coronavirus Downturn Prompts Bitcoiners To Take A Bet On Alternate Markets

Financial news for REGN dated on 2020-03-16: Sanofi And Regeneron Begin Global Kevzara Clinical Trial Program In Patients With 'Severe' Coronavirus

Financial news for REGN dated on 2020-03-13: Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.

Financial news for REGN dated on 2020-03-12: Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.

Financial news for REGN dated on 2020-03-12: Argus Research Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to \$540

Financial news for REGN dated on 2020-03-11: Oppenheimer Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to \$525

Financial news for REGN dated on 2020-03-10: Regeneron, Sanofi To Test Arthritis Drug As Potential Coronavirus Treatment

Financial news for REGN dated on 2020-03-06: The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study

Financial news for REGN dated on 2020-03-05: The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19

Financial news for REGN dated on 2020-03-04: CFRA Downgrades Regeneron Pharmaceuticals to Hold, Raises Price Target to \$487

Financial news for REGN dated on 2020-03-04: Stocks That Hit 52-Week Highs On Wednesday

Financial news for REGN dated on 2020-03-04: Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.

Financial news for REGN dated on 2020-03-02: How The COVID-19 Outbreak Is Benefiting Biotech Investors

Financial news for REGN dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for REGN dated on 2020-02-27: Stocks That Hit 52-Week Highs On Thursday

Financial news for REGN dated on 2020-02-27: 28 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for REGN dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for REGN dated on 2020-02-26: Benzinga's Top Upgrades, Downgrades For February 26, 2020

Financial news for REGN dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for REGN dated on 2020-02-26: Credit Suisse Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to \$510

Financial news for REGN dated on 2020-02-26: 10 Biggest Price Target Changes For Wednesday

Financial news for REGN dated on 2020-02-26: Baird Downgrades Regeneron Pharmaceuticals to Neutral

Financial news for REGN dated on 2020-02-26: Canaccord Genuity Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to \$550

Financial news for REGN dated on 2020-02-25: Regeneron Snags Upgrade On Reduced Prospects For Rival Eye Disorder Drug

Financial news for REGN dated on 2020-02-25: Regeneron Pharmaceuticals shares are trading higher. Jefferies analysts said recent adverse events arising from competitor Novartis' Beovu will likely minimize competitive risk to Regeneron's Eylea franchise.

Financial news for REGN dated on 2020-02-25: Stocks That Hit 52-Week Highs On Tuesday

Financial news for REGN dated on 2020-02-25: UPDATE: Jefferies Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to \$492 As Firm Attributes Optimism Towards 'recent adverse events that have arisen with Novartis' Beovu, which will likely dampen its uptake and minimizes competitive risk.'

Financial news for REGN dated on 2020-02-25: 10 Biggest Price Target Changes For Tuesday

Financial news for REGN dated on 2020-02-25: Jefferies Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to \$492

Financial news for REGN dated on 2020-02-25: Evercore ISI Group Upgrades Regeneron Pharmaceuticals to Outperform

Financial news for REGN dated on 2020-02-24: Chip Stocks, Apple, Airlines Among Hardest Hit As Stocks Plunge On Coronavirus Spread

Financial news for REGN dated on 2020-02-24: Regeneron Shares Higher; It Was Earlier Reported The ASRS Announced Reports Of Vasculitis Tied To Beovu, A Drug From Competitor Novartis

Financial news for REGN dated on 2020-02-11: Benzinga's Top Upgrades, Downgrades For February 11, 2020

Financial news for REGN dated on 2020-02-11: Argus Research Upgrades Regeneron Pharmaceuticals to Buy, Announces \$430 Price Target

Financial news for REGN dated on 2020-02-08: Regeneron Announces Positive Two Year EYLEA Results in Patients with Diabetic Retinopathy at Angiogenesis, Exudation, and Degeneration 2020 Meeting

Financial news for REGN dated on 2020-02-07: Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to \$410

Financial news for REGN dated on 2020-02-06: Regeneron Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.

Financial news for REGN dated on 2020-02-06: Regeneron Executive Says A Set Of Its Treatments Could Be Available For Testing Or Passionate Use In Coronavirus Patients 'Within Few Months'

Financial news for REGN dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for REGN dated on 2020-02-06: Regeneron Pharmaceuticals Q4 Adj. EPS \$7.5 Beats \$6.9 Estimate, Sales \$2.17B Beat \$2.11B Estimate

Financial news for REGN dated on 2020-02-06: Earnings Scheduled For February 6, 2020

Financial news for REGN dated on 2020-02-05: Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.

Financial news for REGN dated on 2020-02-04: Regeneron Reports Expanded Deal with US Dept. Of Health And Human Services To Develop New Treatments Combating Novel Coronavirus

Financial news for REGN dated on 2020-02-04: Department Of Health & Human Services Says It Is Reviewing A Potential Vaccines, Treatments & Diagnostics From Public, Private Sectors To Identify Candidates For Coronavirus Detection

Financial news for REGN dated on 2020-02-04: HHS, Regeneron Collaborate To Develop 2019 nCoV Treatment

Financial news for REGN dated on 2020-02-02: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Financial news for REGN dated on 2020-01-28: Regeneron Pharmaceuticals Earlier Announced It Has Received FDA Approval For Priority Review Dupixent For Children Aged 6 To 11 Years With Moderate-To-Severe Atopic Dermatitis

Financial news for REGN dated on 2020-01-17: Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to \$411

Financial news for REGN dated on 2020-01-13: Regeneron Sees Prelim. US Net Product Sales Of EYLEA Injection ~\$4.64B

Financial news for REGN dated on 2020-01-10: A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations

Financial news for REGN dated on 2020-01-09: Regeneron Highlights Phase 2 Results From Gareto Mab Trial: 'Approximately 25% decrease in total bone lesions (both new and existing) driven by nearly 90% reduction in formation of new lesions'

Financial news for REGN dated on 2019-12-31: 10 Best Performing S&P 500 Stocks Of The Decade

Financial news for REGN dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for REGN dated on 2019-12-24: Benzinga's Top Upgrades, Downgrades For December 24, 2019

Financial news for REGN dated on 2019-12-24: Raymond James Initiates Coverage On

Regeneron Pharmaceuticals with Market Perform Rating

Financial news for REGN dated on 2019-12-18: Quantum Leap Healthcare Collaborative Announces Selection Of Regeneron's Libtayo & REGN3767 For Injection In I-SPY 2 Trial For Breast Cancer

Financial news for REGN dated on 2019-12-16: Benzinga's Top Upgrades, Downgrades For December 16, 2019

Financial news for REGN dated on 2019-12-16: Evercore ISI Group Downgrades Regeneron Pharmaceuticals to In-Line

Financial news for REGN dated on 2019-12-16: Intellia Therapeutics Will Modify its Cost and Profit Share with Regeneron for Development of Transthyretin Amyloidosis From 50% to 25%

Financial news for REGN dated on 2019-12-13: Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 13, 2019: EWU, SRPT, FDX, IHRT, REGN

Financial news for REGN dated on 2019-12-13: Credit Suisse Upgrades Regeneron Pharmaceuticals to Outperform

Financial news for REGN dated on 2019-12-10: Regeneron Shares Swing On Sanofi's Hint At Sale Of Ownership Stake, Amendments To Drug Collaborations

Financial news for REGN dated on 2019-12-10: 25 Stocks Moving in Tuesday's Pre-Market Session

Financial news for REGN dated on 2019-12-09: Hearing Sanofi May Sell Regeneron Stake After Lockup Expires

Financial news for REGN dated on 2019-12-08: Regeneron Announces First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma at ASH 2019

Financial news for REGN dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for REGN dated on 2019-12-05: Regeneron Reports Topline Phase 2 Data From Pozelimab In Patients With Rare Blood Disorder, Shows Results From Initial 6-Patient Cohort Reduced LDH To Normal Levels At Week 8

Financial news for REGN dated on 2019-11-19: Medicines Company Shares Soar On Rumored Buyout Interest From Novartis

Financial news for REGN dated on 2019-11-12: Benzinga's Top Upgrades, Downgrades For November 12, 2019

Financial news for REGN dated on 2019-11-12: SunTrust Robinson Humphrey Initiates Coverage On Regeneron Pharmaceuticals with Hold Rating, Announces \$360 Price Target

Financial news for REGN dated on 2019-11-07: UPDATE: Citi On Regeneron Continues 'to remain bullish on Dupixent and see \$10B peak sales vs current run-rate of ~\$2.5B within 3 years of launch. We are less concerned about the Dupi competition as we think the safety profile of Dupi sets it apart'

Financial news for REGN dated on 2019-11-07: UPDATE: Citi Upgrades Regeneron To Buy, Raises Target To \$420 As Firm Notes 'We think between Libtayo data next year and continuous Dupi growth, investors will find it easy to stay invested through near-term Eylea competition'

Financial news for REGN dated on 2019-11-07: Benzinga's Top Upgrades, Downgrades For November 7, 2019

Financial news for REGN dated on 2019-11-07: Citigroup Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to \$420

Financial news for REGN dated on 2019-11-06: UPDATE: Morgan Stanley On Regeneron Also Awaits 'clearer data on Beovu's impact in 4Q'

Financial news for REGN dated on 2019-11-06: UPDATE: Morgan Stanley Maintains Equal-Weight On Regeneron, Raises Target To \$387 As Firm Notes 'Eylea outperformed and cost control continued in the JV improving profitability. Pipeline updates from NSCLC, bispecifics and C5 were encouraging'

Financial news for REGN dated on 2019-11-06: AstraZeneca Named The Most Innovative Global Pharma Company

Financial news for REGN dated on 2019-11-06: 16 S&P 500 Stocks With The Most Insider

Ownership

Financial news for REGN dated on 2019-11-06: BMO Capital Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to \$358

Financial news for REGN dated on 2019-11-06: Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to \$387

Financial news for REGN dated on 2019-11-06: 10 Biggest Price Target Changes For Wednesday

Financial news for REGN dated on 2019-11-06: Regeneron, Vyriad Reports Strategic Deal For Discovery, Development Of New Oncolytic Virus Treatments For Cancer, No Terms Disclosed

Financial news for REGN dated on 2019-11-06: Credit Suisse Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to \$340

Financial news for REGN dated on 2019-11-05: Regeneron Pharmaceuticals Says In Sept. Received A Civil Investigative Demand From The DOJ Pursuant To The Federal False Claims Act

Financial news for REGN dated on 2019-11-05: Regeneron Pharmaceuticals shares are trading higher after the company reported Q3 EPS and sales results up from last year. The company also reported a \$1 billion buyback.

Financial news for REGN dated on 2019-11-05: 10 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for REGN dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for REGN dated on 2019-11-05: Regeneron Pharmaceuticals Sees FY19 Sanofi Collaboration Revenue \$490M-\$510M

Financial news for REGN dated on 2019-11-05: Regeneron Reports \$1B Buyback

Financial news for REGN dated on 2019-11-05: Regeneron Pharmaceuticals Q3 EPS \$6.67 Up From \$5.87 YoY, Sales \$2.048B Up From \$1.663B YoY

Financial news for REGN dated on 2019-11-03: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Financial news for REGN dated on 2019-10-29: Regeneron And Sanofi Announce European Commission Approval Of A New Indication For Dupixent In Severe Chronic Rhinosinusitis With Nasal Polyposis

Financial news for REGN dated on 2019-10-28: 11 Stocks With The Highest Gross Margins

Financial news for REGN dated on 2019-10-17: Bank of America Reinstates Neutral on Regeneron Pharmaceuticals, Announces \$325 Price Target

Financial news for REGN dated on 2019-10-09: Canaccord Genuity Maintains Hold on Regeneron Pharmaceuticals, Lowers Price Target to \$320

Financial news for REGN dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for REGN dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for REGN dated on 2019-09-23: Benzinga's Top Upgrades, Downgrades For September 23, 2019

Financial news for REGN dated on 2019-09-23: Guggenheim Upgrades Regeneron Pharmaceuticals to Buy

Financial news for REGN dated on 2019-09-20: Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.

Financial news for REGN dated on 2019-09-20: CHMP Recommends Approval Of Regeneron's Dupixent For Severe Chronic Rhinosinusitis With Nasal Polyposis

Financial news for REGN dated on 2019-09-10: Biotech Stock On The Radar: Aimmune Awaits Adcom Test

Financial news for REGN dated on 2019-09-10: The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris

Financial news for REGN dated on 2019-08-29: The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings

Financial news for REGN dated on 2019-08-28: Stocks That Hit 52-Week Lows On Wednesday

Financial news for REGN dated on 2019-08-28: The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved

Financial news for REGN dated on 2019-08-27: The Daily Biotech Pulse: Nuvecra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO

Financial news for REGN dated on 2019-08-20: Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster

Financial news for REGN dated on 2019-08-14: Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially signaling an oncoming recession.

Financial news for REGN dated on 2019-08-14: Regeneron's Drug To Treat Genetic Form Of Bad Cholesterol Aces Late-Stage Trial

Financial news for REGN dated on 2019-08-14: The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering

Financial news for REGN dated on 2019-08-14: Regeneron Announces Phase 3 Trial Of Evinacumab In Patients With Severe, Inherited Form Of High Cholesterol Met Primary Endpoint

Financial news for REGN dated on 2019-08-13: Regeneron's Eylea Prefilled Syringe Clears FDA Hurdle

Financial news for REGN dated on 2019-08-13: A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Consumer Price Index

Financial news for REGN dated on 2019-08-13: Regeneron Pharmaceuticals Receives FDA Approval For EYLEA Injection Prefilled Syringe

Financial news for REGN dated on 2019-08-12: Regeneron Pharma Reports Has Been Informed By Study Investigators That Trial Evaluating 4 Therapies For Ebola Stopped Early Because REGN-EB3 Was Superior To ZMapp In Preventing Death

Financial news for REGN dated on 2019-08-07: Baird Upgrades Regeneron Pharmaceuticals to Outperform

Financial news for REGN dated on 2019-08-06: 28 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for REGN dated on 2019-08-06: Regeneron Pharmaceuticals Reports Q2 Earnings Beat

Financial news for REGN dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for REGN dated on 2019-08-06: Regeneron Pharmaceuticals Q2 Adj. EPS \$6.04 Beats \$5.37 Estimate, Sales \$1.93B Beat \$1.8B Estimate

Financial news for REGN dated on 2019-08-06: Earnings Scheduled For August 6, 2019

Financial news for REGN dated on 2019-08-06: Sanofi/Regeneron Dupixent Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years With Severe Atopic Dermatitis

Financial news for REGN dated on 2019-07-11: Regeneron shares trading lower following news Praluent will be pulled from Germany. A Mizuho analyst said the news has positive implications for Amgen's Repatha and The Medicine Company's Inclisiran

Financial news for REGN dated on 2019-07-11: Mizuho Comments On News Praluent Will Be Pulled From Germany, Sees Positive Implications For Amgen's Repatha, The Medicine Co.'s Inclisiran

Financial news for REGN dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal

to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for REGN dated on 2019-07-10: Shares of several healthcare companies in the pharmaceutical space are trading lower after Amneal Pharmaceuticals announced a cost reduction plan in response to the continuing industry challenges. Amneal cut guidance as part of plan.

Financial news for REGN dated on 2019-07-01: Regeneron Pharma Reports Libtayo Was Approved For Advanced Cutaneous Squamous Cell Carcinoma In EU

Financial news for REGN dated on 2019-06-28: Regeneron Pharma Reports CHMP Recommended Approval Of Dupixent For Moderate To Severe Atopic Dermatitis In Adolescents

Financial news for REGN dated on 2019-06-26: Regeneron Pharmaceuticals And Sanofi Announce That The FDA Has Approved Dupixent (Dupilumab) For Use With Other Medicines To Treat Chronic Rhinosinusitis With Nasal Polyposis In Adults Whose Disease Is Not Controlled

Financial news for REGN dated on 2019-06-26: The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart

Financial news for REGN dated on 2019-06-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Financial news for REGN dated on 2019-06-21: The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy

Financial news for REGN dated on 2019-06-21: Sanofi, Regeneron Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma

Financial news for REGN dated on 2019-06-18: UPDATE: Argus Downgrades Regeneron To Hold As Firm Notes Co's 'primary revenue-generating drug, Eylea faces threats from competing products and the expiration of its patents'

Financial news for REGN dated on 2019-06-18: Argus Downgrades Regeneron Pharmaceuticals to Hold

Financial news for REGN dated on 2019-06-14: Regeneron Announces CD20xCD3 Bispecific REGN1979 Shows 'Positive' Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures

Financial news for REGN dated on 2019-06-08: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Financial news for REGN dated on 2019-05-31: Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

Financial news for REGN dated on 2019-05-31: Shares of many healthcare companies are trading lower following a tweet from President Trump late Thursday stating the US will impose a 5 percent tariff on goods from Mexico.

Financial news for REGN dated on 2019-05-23: Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Inc. - Common Stock, Lowers Price Target to \$340

Financial news for REGN dated on 2019-05-21: Credit Suisse Initiates Coverage On Regeneron Pharmaceuticals, Inc. - Common Stock with Neutral Rating, Announces \$336 Price Target

Financial news for REGN dated on 2019-05-20: Regeneron Shares Initiated With Neutral Rating, \$336 Price Target By Credit Suisse

Financial news for REGN dated on 2019-05-16: Regeneron, Sanofi Highlight Positive Updated Data For Libtayo In Locally-Advanced, Metastatic Cutaneous Squamous Cell Carcinoma Will Be Shared At 2019 ASCO

Financial news for REGN dated on 2019-05-15: Temasek 13F Shows Liquidated Positions In Antero Resources, Regeneron, Ctrip, Turquoise Hill Resources

Financial news for REGN dated on 2019-05-14: The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings

Financial news for REGN dated on 2019-05-13: Regeneron Pharma Reports FDA Approved EYLEA Injection For Diabetic Retinopathy

Financial news for REGN dated on 2019-05-13: FDA Approves Eylea Injection For

Diabetic Retinopathy

Financial news for REGN dated on 2019-05-13: Cantor Fitzgerald Maintains Neutral on Regeneron Pharmaceuticals, Inc. - Common Stock, Lowers Price Target to \$405

Financial news for REGN dated on 2019-05-11: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for REGN dated on 2019-05-08: Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Wed., May 8, 2019

Financial news for REGN dated on 2019-05-08: UBS Maintains Buy on Regeneron Pharmaceuticals, Inc. - Common Stock, Lowers Price Target to \$440

Financial news for REGN dated on 2019-05-08: BMO Capital Maintains Market Perform on Regeneron Pharmaceuticals, Inc. - Common Stock, Lowers Price Target to \$375

Financial news for REGN dated on 2019-05-08: Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Inc. - Common Stock, Lowers Price Target to \$389

Financial news for REGN dated on 2019-05-07: Regeneron Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 EPS and sales.

Financial news for REGN dated on 2019-05-07: Regeneron, Sanofi Report Dupixent Approved For Severe Asthma By EC

Financial news for REGN dated on 2019-05-07: The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex

Financial news for REGN dated on 2019-05-07: Regeneron Pharmaceuticals Q1 Adj. EPS \$4.45 Misses \$5.46 Estimate, Sales \$1.71B Miss \$1.76B Estimate

Financial news for REGN dated on 2019-05-07: 10 Stocks To Watch For May 7, 2019

Financial news for REGN dated on 2019-05-07: Earnings Scheduled For May 7, 2019

Financial news for REGN dated on 2019-05-04: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for REGN dated on 2019-05-02: 5 Biotech Stocks With Near-Term Catalysts Ahead

Financial news for REGN dated on 2019-04-30: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

Financial news for REGN dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for REGN dated on 2019-04-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Financial news for REGN dated on 2019-04-26: Regeneron, Sanofi Report CHMP Issued Positive Opinion For Libtayo

Financial news for REGN dated on 2019-04-25: Replimune's Lead Asset Likely To Clear Regulatory Hurdle, Wedbush Says In Bullish Initiation

Financial news for REGN dated on 2019-04-18: Shares of several healthcare companies are trading lower on continued weakness over concerns of 'Medicare for all' support within 2020 presidential candidates and the uncertainty over healthcare policy going into the election.

Financial news for REGN dated on 2019-04-17: Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.

Financial news for REGN dated on 2019-04-08: Regeneron, Alnylam Strike \$1B Collaboration For RNAi-based Therapeutics

Financial news for REGN dated on 2019-04-08: UPDATE: Alnylam Will Be Eligible For Added \$200M In Potential Near-Term Milestones

Financial news for REGN dated on 2019-04-08: UPDATE: Regeneron Will Invest \$800M In Alnylam Through Upfront Cash, Equity Investment

Financial news for REGN dated on 2019-04-08: Alnylam, Regeneron Report Collaboration To Discover, Develop, Commercialize RNAi Therapeutics Focused On Ocular, Central

Nervous System Diseases

Financial news for REGN dated on 2019-03-29: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for REGN dated on 2019-03-18: Regeneron Late Friday Announced Praluent HAS Been approved In European Union

Financial news for REGN dated on 2019-03-15: Regeneron Pharmaceuticals Announces Praluent Is Not Approved In EU

Financial news for REGN dated on 2019-03-13: Regeneron And Sanofi To Present New Praluent Data At ACC.19

Financial news for REGN dated on 2019-03-11: Regeneron Press Release confirms FDA Approval Of Dupixent For Moderate-To-severe Atopic Dermatitis In Adolescents

Financial news for REGN dated on 2019-03-11: Regeneron Pharmaceuticals Supplemental Submission For Dupixent Wins FDA Approval

Financial news for REGN dated on 2019-03-10: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

Financial news for REGN dated on 2019-03-08: The Daily Biotech Pulse: Tonix Gets European Patent, EC Nod For Roche, Insys Earnings

Financial news for REGN dated on 2019-03-08: Sanofi Announces FDA to Undertake Priority Review of Dupixent for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps

Financial news for REGN dated on 2019-03-04: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Financial news for REGN dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for REGN dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for REGN dated on 2019-02-25: Regeneron, Sanofi Issue Press Release Highlighting 'Strongly Disagree' With Verdict To Uphold 3 Of 5 Amgen US Patent Claims Related To PCSK9 Antibodies

Financial news for REGN dated on 2019-02-25: Jury Finds Amgen's Patents For Repatha Are Valid; Sanofi, Regeneron Have Lost Validity Trial, Conceded Infringement

Financial news for REGN dated on 2019-02-25: Regeneron, Sanofi Highlight Detailed Results From 2 Phase 3 Trials In Adults With Recurring Severe Chronic Rhinosinusitis With Nasal Polyps

Financial news for REGN dated on 2019-02-22: 8 Biggest Price Target Changes For Friday

Financial news for REGN dated on 2019-02-22: Guggenheim Downgrades Regeneron Pharmaceuticals to Neutral, Lowers Price Target to \$425

Financial news for REGN dated on 2019-02-15: US And EU Patent Office Decisions Invalidate Amgen Subsidiary Immunex's Patents Claiming Antibodies To IL-4 Receptor

Financial news for REGN dated on 2019-02-14: '*SANOFI, REGENERON WIN IPR CHALLENGE TO AMGEN ANTIBODY PATENT' -Tweets zbiotech

Financial news for REGN dated on 2019-02-11: Regeneron and Sanofi Offer Praluent at a New Reduced US List Price

Financial news for REGN dated on 2019-02-09: Regeneron Announces One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium

Financial news for REGN dated on 2019-02-06: The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

Financial news for REGN dated on 2019-02-06: Regeneron Pharmaceuticals Sees FY19 Sanofi Collaboration Revenue Of \$510M-\$560M

Financial news for REGN dated on 2019-02-06: Regeneron Pharmaceuticals Q4 Adj. EPS \$6.84 Beats \$5.72 Estimate, Sales \$1.93B Beat \$1.71B Estimate

Financial news for REGN dated on 2019-02-06: Earnings Scheduled For February 6, 2019

Financial news for REGN dated on 2019-02-05: Regeneron Pharmaceuticals Q4 Earnings Preview

Financial news for REGN dated on 2019-02-04: Sanofi Says CHMP Recommends Approval Of Praluent To Reduce Cardiovascular Risk In People With Established Atherosclerotic Cardiovascular Disease

Financial news for REGN dated on 2019-02-03: The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs

Financial news for REGN dated on 2019-02-01: The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of Titan's Opioid Disorder Treatment Implant

Financial news for REGN dated on 2019-01-18: The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug

Financial news for REGN dated on 2019-01-07: US Supreme Court Rejects Amgen Bid To Reinstate Patent Verdict Against Sanofi And Regeneron Over Cholesterol Medication

Financial news for REGN dated on 2019-01-07: Sanofi, Regeneron Restructure Immunology Collaboration for Discovery and Development Programs; Sanofi to Pay Regeneron \$462M Plus Up to \$120M in Development Costs

Financial news for REGN dated on 2019-01-04: Guggenheim Upgrades Regeneron Pharmaceuticals to Buy

Financial news for REGN dated on 2018-12-28: The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO

Financial news for REGN dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for REGN dated on 2018-12-14: Goldman Sachs Upgrades Regeneron Pharmaceuticals to Buy; Added To Its 'Conviction Buy' List

Financial news for REGN dated on 2018-11-12: Ziopharm Oncology Announces Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer

Financial news for REGN dated on 2018-11-12: Ziopharm Oncology Announces Immunology Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer

Financial news for REGN dated on 2018-11-06: Sanofi Reports FDA Accepted For Priority Review For Supplemental Biologics License Application For Dupixent In Adolescent Patients 12-17 Years Of Age

Financial news for REGN dated on 2018-11-06: The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

Financial news for REGN dated on 2018-11-06: UPDATE: Regeneron Cuts FY18 Sanofi Collaboration Sales From \$455M-\$485M To \$430M-\$455M

Financial news for REGN dated on 2018-11-06: Regeneron Cuts Guidance

Financial news for REGN dated on 2018-11-06: Regeneron Pharmaceuticals, Inc. Q3 EPS \$5.87 Beats \$5.18 Estimate, Sales \$1.663B Beat \$1.64B Estimate

Financial news for REGN dated on 2018-11-06: Earnings Scheduled For November 6, 2018

Financial news for REGN dated on 2018-11-05: Regeneron Pharmaceuticals Q3 Earnings Preview

Financial news for REGN dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for REGN dated on 2018-10-25: Regeneron Offers an Update on its Complete Response Letter From the FDA, Says Will Resubmit the Prior-Approval Supplement in Early 2019 and Expects a 2019 Launch of the EYLEA Pre-Filled Syringe

Financial news for REGN dated on 2018-10-25: Regeneron's Phase 3 Trial Evaluating EYLEA Met its Primary and Key Secondary Endpoints

Financial news for REGN dated on 2018-10-22: A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street

Financial news for REGN dated on 2018-10-22: Regeneron Reports FDA Approved Asthma Indication For Dupixent

Financial news for REGN dated on 2018-10-16: Regeneron Highlights 2 Phase 3 Trials Of Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Dupixent: 'significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery'

Financial news for REGN dated on 2018-10-16: Sanofi, Regeneron Announce Dupixent Showed Positive Topline Results in Two Phase 3 Trials of Patients With Chronic Rhinosinusitis With Nasal Polyps

Financial news for REGN dated on 2018-10-15: Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients

Financial news for REGN dated on 2018-10-14: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for REGN dated on 2018-10-11: Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to \$412

Financial news for REGN dated on 2018-10-11: Canaccord Genuity Maintains Hold on Regeneron Pharmaceuticals, Raises Price Target to \$410

Financial news for REGN dated on 2018-10-01: Cantor Fitzgerald Initiates Coverage On Regeneron Pharmaceuticals with Neutral Rating, Announces \$415 Price Target

Financial news for REGN dated on 2018-09-28: FDA Approves Regeneron And Sanofi's Libtayo (cemiplimab-rwlc) As First And Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma

Financial news for REGN dated on 2018-09-26: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Financial news for REGN dated on 2018-09-25: Analyst: Amarin's Vascepa Results Create Unicorn Potential, M&A Opportunity

Financial news for REGN dated on 2018-09-19: 5 Stocks Primed To Fall Lower In The Coming Days

Financial news for REGN dated on 2018-09-13: Regeneron Pharma Reports FDA Will Review EYLEA Injection For Treatment Of Diabetic Retinopathy

Financial news for REGN dated on 2018-09-12: Sanofi, Regeneron Report FDA Will Review Supplemental Biologics License Application For Praluent For Treatment To Reduce Major Adverse Cardiovascular Events

Financial news for REGN dated on 2018-09-12: Sanofi, Regeneron Announces FDA to Review Supplemental Biologics License Application for Praluent Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events

Financial news for REGN dated on 2018-09-10: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for REGN dated on 2018-08-24: The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict

Financial news for REGN dated on 2018-08-24: REMINDER: Regeneron Has FDA PDUFA Date Today For Praluent

Financial news for REGN dated on 2018-08-20: The Week Ahead: Alibaba, More Retail Earnings Take Center Stage

Financial news for REGN dated on 2018-08-17: Regeneron Pharmaceuticals Announces The FDA Approves EYLEA

Financial news for REGN dated on 2018-08-16: Teva Pharmaceuticals shares are up 4.4% and Regeneron shares are trading up 2.5% after the companies reported positive results from a Phase 3 study of fasinumab for osteoarthritis pain.

Financial news for REGN dated on 2018-08-16: Regeneron and Teva Announce Phase 3 Fasinumab Met Both Co-Primary Endpoints And All Secondary Endpoints

Financial news for REGN dated on 2018-08-13: Regeneron Gets a Complete Response Letter From the FDA for EYLEA Due to Ongoing Labeling Discussions, Expects to Receive a Final FDA Action Within 2 Months

Financial news for REGN dated on 2018-08-10: The Daily Biotech Pulse: Puma, CareDx

Soar On Earnings, Corcept Plunges On Bottom-Line Miss

Financial news for REGN dated on 2018-08-09: REMINDER: Regeneron Has FDA PDUFA Date Saturday Aug. 11th for its sBLA for Eylea in Wet AMD

Financial news for REGN dated on 2018-08-06: Regeneron To Make \$100M bluebird bio Investment In Cancer Research Collaboration

Financial news for REGN dated on 2018-08-06: Benzinga Pro's 5 Stocks To Watch Today

Financial news for REGN dated on 2018-08-06: Barclays Maintains Underweight on Regeneron Pharmaceuticals, Raises Price Target to \$305

Financial news for REGN dated on 2018-08-06: bluebird bio and Regeneron Announce Cancer Collaboration, Regeneron to Invest \$100M in bluebird Stock at \$238.10/Share

Financial news for REGN dated on 2018-08-05: The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs

Financial news for REGN dated on 2018-08-03: Canaccord Genuity Maintains Hold on Regeneron Pharmaceuticals, Raises Price Target to \$390

Financial news for REGN dated on 2018-08-03: Benzinga's Top Upgrades, Downgrades For August 3, 2018

Financial news for REGN dated on 2018-08-03: Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to \$409

Financial news for REGN dated on 2018-08-03: A Peek Into The Markets: US Stock Futures Edge Higher; All Eyes On Jobs Report

Financial news for REGN dated on 2018-08-03: Baird Downgrades Regeneron Pharmaceuticals to Neutral

Financial news for REGN dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for REGN dated on 2018-08-02: Regeneron Narrows FY18 Guidance For Sanofi Collaboration Sales From \$450M-\$485M To \$455M-\$485M

Financial news for REGN dated on 2018-08-02: Regeneron Pharmaceuticals Q2 EPS \$5.45 Beats \$4.70 Estimate, Sales \$1.608B Beat \$1.56B Estimate

Financial news for REGN dated on 2018-08-02: Earnings Scheduled For August 2, 2018

Financial news for REGN dated on 2018-08-01: Regeneron Pharmaceuticals Earnings Outlook

Financial news for REGN dated on 2018-08-01: Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Financial news for REGN dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for REGN dated on 2018-07-20: Intellia Therapeutics 8-K Indicates Co. And Regeneron Agreed To Form Co-Development And Co-Promotion Agreement Consistent With April 2016 Collaboration Deal

Financial news for REGN dated on 2018-07-16: Argus Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to \$415

Financial news for REGN dated on 2018-07-13: Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to \$396

Financial news for REGN dated on 2018-06-27: Oppenheimer Upgrades Regeneron Pharmaceuticals to Outperform

Financial news for REGN dated on 2018-06-21: Inovio Reports Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor

Financial news for REGN dated on 2018-06-20: Watching Shares of Regeneron After Traders Circulate Unconfirmed Chatter Of Offer From Sanofi

Financial news for REGN dated on 2018-06-11: Crispr Therapeutics Falls As Studies Suggest Possible Cancerous Side Effect

Financial news for REGN dated on 2018-06-11: Intellia Therapeutics Shares Down 10% Over Last 45 Mins. Following STAT News Article On CRISPR Sickle-Cell, Thalassemia

Programs 'should not affect the gene-disruption approach Intellia Therapeutics and Regeneron' Use

Financial news for REGN dated on 2018-06-06: Regeneron, Zoetis Report Collaboration To Research Antibody Therapies For Use In Animal Health

Financial news for REGN dated on 2018-06-04: Regeneron, Sanofi Report New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Results in Advanced Cutaneous Squamous Cell Carcinoma

Financial news for REGN dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for REGN dated on 2018-06-01: Jim Cramer Shares His Thoughts On Lululemon, Regeneron And More

Financial news for REGN dated on 2018-05-31: Regeneron Announces It's Shipping Investigational Ebola Treatment REGN-EB3 To Democratic Republic of the Congo For Use In Current Outbreak

Financial news for REGN dated on 2018-05-21: Sanofi, Regeneron Announce New England Journal of Medicine Published 2 Positive Phase 3 Trials Showing Dupixent (dupilumab) Improved Moderate-to-Severe Asthma

Financial news for REGN dated on 2018-05-16: Sanofi, Regeneron Announce Dupixent Phase 3 Trial in Adolescents With Inadequately Controlled Moderate-to-severe Atopic Dermatitis Met Primary, Secondary Endpoints

Financial news for REGN dated on 2018-05-09: Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

Financial news for REGN dated on 2018-05-07: Stocks That Made New 52-Week Lows Today Include: Colgate-Palmolive, Acuity Brands, International Flavors & Fragrances, Regeneron, Celgene, L Brands, and Dentsply Sirona

Financial news for REGN dated on 2018-05-04: Stocks That Made New 52-Week Lows Today Include Regeneron and L Brands

Financial news for REGN dated on 2018-05-04: Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to \$370.00

Financial news for REGN dated on 2018-05-04: BMO Capital Maintains Market Perform on Regeneron Pharmaceuticals, Lowers Price Target to \$361.00

Financial news for REGN dated on 2018-05-04: Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down

Financial news for REGN dated on 2018-05-04: Jim Cramer Shares His Thoughts On Blackstone, Celgene And More

Financial news for REGN dated on 2018-05-03: Stocks That Made New 52-Week Lows Today Include Colgate-Palmolive, Philip Morris, Regeneron, Corning, Hanesbrands, Bed Bath & Beyond, Pepsi, Coca-Cola, Paccar, Johnson & Johnson, Mallinckrodt, CBS, DISH Network, Goodyear Tire, Chubb, Hershey, and AT&T

Financial news for REGN dated on 2018-05-03: Regeneron Pharmaceuticals: Sequencing Its Way to +30% Upside

Financial news for REGN dated on 2018-05-03: Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss

Financial news for REGN dated on 2018-05-03: Regeneron Pharmaceuticals Q1 EPS \$4.67 Beats \$4.32 Estimate, Sales \$1.51B Beat \$1.51B Estimate

Financial news for REGN dated on 2018-05-03: Earnings Scheduled For May 3, 2018

Financial news for REGN dated on 2018-05-02: Esperion Shares Plunge After Cholesterol-Lowering Drug's Phase 3 Results Stir Safety Concerns

Financial news for REGN dated on 2018-05-01: Stocks That Made New 52-Week Low Today Include: CBS, Goodyear Tire, Vulcan Materials, Regeneron, Hershey, Leggett & Platt, Harley-Davidson, Kraft Heinz, Kellogg, Mallinckrodt, Fortune Brands Home, Comcast, Pepsi, and Acuity Brands

Financial news for REGN dated on 2018-05-01: Benzinga's Top Upgrades, Downgrades For May 1, 2018

Financial news for REGN dated on 2018-05-01: Guggenheim Downgrades Regeneron Pharmaceuticals to Neutral

Financial news for REGN dated on 2018-05-01: Regeneron and Sanofi to Lower the Price of Praluent Injection in Exchange for 'Straightforward, More Affordable' Patient Access for Express Scripts Patients

Financial news for REGN dated on 2018-04-30: Stocks That Made New 52-Week Lows Today Include: Arconic, Mohawk Industries, Comcast, DISH Network, Regeneron, and Skyworks Solutions

Financial news for REGN dated on 2018-04-30: Sanofi Announces FDA to Conduct Priority Review of Cemiplimab as Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

Financial news for REGN dated on 2018-04-29: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Financial news for REGN dated on 2018-04-27: Stocks That Made New 52-Week Highs Today Include: AES and Macy's; Stocks That Made New 52-Week Lows Today Include: Regeneron Pharma, DISH Network, Comcast, and Charter Communications

Financial news for REGN dated on 2018-04-17: Alnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'

Financial news for REGN dated on 2018-04-09: Benzinga's Top Upgrades, Downgrades For April 9, 2018

Financial news for REGN dated on 2018-04-09: The Market In 5 Minutes: Deutsche Bank, GM, Trump, WrestleMania And More

Financial news for REGN dated on 2018-04-09: Raymond James Downgrades Regeneron Pharmaceuticals to Market Perform

Financial news for REGN dated on 2018-04-03: Regeneron, Sanofi Announce EMA to Review DUPIXENT as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma

Financial news for REGN dated on 2018-04-03: Regeneron, Sanofi Announce EMA to Review Cemiplimab as Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

Financial news for REGN dated on 2018-03-21: Regeneron and Alnylam Pharmaceuticals Announce Collaboration for Nonalcoholic Steatohepatitis

Financial news for REGN dated on 2018-03-19: A Peek Into The Markets: U.S. Stock Futures Down; NASDAQ Futures Tumble Over 2%

Financial news for REGN dated on 2018-03-19: Regeneron's EYLEA Meets 24-Week Primary Endpoint In Its Phase 3 PANORAMA Trial

Financial news for REGN dated on 2018-03-12: Strong Trial Results, Effective Distribution Could Put Regeneron's Praluent 'Back In The Competition'

Financial news for REGN dated on 2018-03-12: Meg Tirrell Tweets: Coming up on @SquawkStreet: \$REGN CEO Len Schleifer. What do you want to know?

Financial news for REGN dated on 2018-03-12: Regeneron And Sanofi On Saturday Announced Plan To Expand Accessibility And Affordability Of Praluent, Will Offer Reduced Net Price To Payers Willing To Reduce Access Barriers For Highest-Risk Patients

Financial news for REGN dated on 2018-03-11: Report: The 10 Most Overpaid S&P 500 CEOs

Financial news for REGN dated on 2018-03-10: Sanofi, Regeneron Announce ODYSSEY OUTCOMES Trial Met Primary Endpoint

Financial news for REGN dated on 2018-03-05: ICYMI: Valeant, Overstock And Biotechs

Financial news for REGN dated on 2018-03-05: 7 Biotech Stocks With Clinical Trial Outcomes In March

Financial news for REGN dated on 2018-03-02: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for REGN dated on 2018-03-02: Regeneron, Sanofi Announce FDA to Review DUPIXENT as Potential Treatment for Moderate-to-Severe Asthma

Financial news for REGN dated on 2018-02-21: Canaccord Slices Regeneron Price Target 32% On Eylea, Dupixent Challenges

Financial news for REGN dated on 2018-02-21: Benzinga's Top Upgrades, Downgrades For

February 21, 2018

Financial news for REGN dated on 2018-02-21: Canaccord Genuity Downgrades Regeneron Pharmaceuticals to Hold

Financial news for REGN dated on 2018-02-14: Companies That Earlier Made New 52-Wk Highs Include Coty, S&P Global, and Estee Lauder; Those That Made New 52-Wk Lows Include Regeneron Pharma, Vornado Realty, Federal Realty Investment, and Allergan

Financial news for REGN dated on 2018-02-09: BMO Capital Maintains Market Perform on Regeneron Pharmaceuticals, Lowers price target to \$398.00

Financial news for REGN dated on 2018-02-09: Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises price target to \$415.00

Financial news for REGN dated on 2018-02-09: Analyst: Regeneron Is Undervalued By The Street

Financial news for REGN dated on 2018-02-09: Benzinga's Top Upgrades, Downgrades For February 9, 2018

Financial news for REGN dated on 2018-02-09: Leerink Swann Maintains Outperform on Regeneron Pharmaceuticals, Lowers price target to \$502.00

Financial news for REGN dated on 2018-02-09: Baird Upgrades Regeneron Pharmaceuticals to Outperform

Financial news for REGN dated on 2018-02-09: BTIG Research Downgrades Regeneron Pharmaceuticals to Neutral

Financial news for REGN dated on 2018-02-08: A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Jobless Claims, Fed Speakers

Financial news for REGN dated on 2018-02-08: Regeneron Reports Q4 Adj. EPS \$5.23 vs \$4.53 Est., Sales \$1.58B vs \$1.5B Est.

Financial news for REGN dated on 2018-02-08: Earnings Scheduled For February 8, 2018

Financial news for REGN dated on 2018-02-05: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for REGN dated on 2018-01-29: AbbVie Shares Double In A Year; Leerink Moves To Sidelines

Financial news for REGN dated on 2018-01-22: Regeneron Announces Approval of DUPIXENT in Japan for the Treatment of Atopic Dermatitis

Financial news for REGN dated on 2018-01-12: Lightning Round: Jim Cramer Advises His Viewers On Chegg, Floor & Decor, Regeneron, And More

Financial news for REGN dated on 2018-01-08: How To Trade The JPMorgan Healthcare Conference

Financial news for REGN dated on 2018-01-08: JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma

Financial news for REGN dated on 2018-01-08: Regeneron, Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs From \$1B To \$1.64B

Financial news for REGN dated on 2018-01-05: BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A

Financial news for REGN dated on 2017-12-27: Merus Says the US Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision, This Affirms Merus' Inequitable Conduct Claim Against Regeneron for a Patent

Financial news for REGN dated on 2017-12-18: Regeneron and ISA Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration

Financial news for REGN dated on 2017-12-15: Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More

Financial news for REGN dated on 2017-12-13: Deutsche Bank Initiates Coverage On Regeneron Pharmaceuticals with Hold Rating, Announces \$397.00 Price Target

Financial news for REGN dated on 2017-12-13: Regeneron, Sanofi Announce Positive

Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma

Financial news for REGN dated on 2017-12-11: Regeneron Reports FDA Accepted sBLA Filing For 12-Week Dosing Of EYLEA Injection For Patients With Wet AMD

Financial news for REGN dated on 2017-12-07: 31 Stocks Moving In Thursday's Mid-Day Session

Financial news for REGN dated on 2017-12-07: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for REGN dated on 2017-12-01: Citi Downgrades Regeneron, Citing 'Underappreciated' Risk

Financial news for REGN dated on 2017-12-01: The Market In 5 Minutes: Tax Bill, Bitcoin, 'Today' Show, And More

Financial news for REGN dated on 2017-12-01: Benzinga's Top Upgrades, Downgrades For December 1, 2017

Financial news for REGN dated on 2017-12-01: Citigroup Downgrades Regeneron Pharmaceuticals to Neutral

Financial news for REGN dated on 2017-11-29: Regeneron to Collaborate with Decibel Therapeutics to Discover and Develop Therapeutics for Hearing Loss and Tinnitus

Financial news for REGN dated on 2017-11-28: What's Next For Regeneron After A Therapy Trial Failure?

Financial news for REGN dated on 2017-11-28: Despite Nesvacumab Failure, BTIG Remains Buy Rated On Regeneron Pharmaceuticals As The 2018 Pipeline Could 'Improve Visibility For Future Diversification Of Regeneron's Revenues'

Financial news for REGN dated on 2017-11-28: BTIG Research Maintains Buy on Regeneron Pharmaceuticals, But Lowers Price Target From \$520 to \$480 On The Heels Of Monday's Announcement That Nesvacumab Didn't Meet Clinical Study Endpoints And Won't Enter Phase 3 Development

Financial news for REGN dated on 2017-11-27: Regeneron Announces EYLEA Injection and Nesvacumab Combination Program did Not Provide Sufficient Differentiation to Warrant Phase 3 Development

Financial news for REGN dated on 2017-11-14: 34 Stocks Moving In Tuesday's Pre-Market Session

Financial news for REGN dated on 2017-11-09: BMO Capital Maintains Market Perform on Regeneron Pharmaceuticals, Lowers Price Target to \$479.00

Financial news for REGN dated on 2017-11-09: Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to \$463.00

Financial news for REGN dated on 2017-11-08: A Big Biotech ETF Is About To Get Cheaper

Financial news for REGN dated on 2017-11-08: Regeneron Surrenders Most Early Gains After Q3 Beat

Financial news for REGN dated on 2017-11-08: Regeneron Reaffirms FY17 EYLEA US Net Product Sales ~10% YoY

Financial news for REGN dated on 2017-11-08: Regeneron Reports Q3 Adj. EPS \$3.99 vs \$3.85 Est., Sales \$1.501B vs \$1.46B Est.

Financial news for REGN dated on 2017-11-08: Earnings Scheduled For November 8, 2017

Financial news for REGN dated on 2017-11-03: Regeneron Pharmaceuticals Gains A Bull Ahead Of Earnings

Financial news for REGN dated on 2017-11-03: Benzinga's Top Upgrades, Downgrades For November 3, 2017

Financial news for REGN dated on 2017-11-03: The Market In 5 Minutes: Apple, iPhones, And Trump's Twitter

Financial news for REGN dated on 2017-11-03: Baird Upgrades Regeneron Pharmaceuticals to Neutral

Financial news for REGN dated on 2017-11-01: Inovio Initiates Phase 1b/2a Study Of

INO-5401 In Combination With Regeneron's PD-1 Inhibitor

Financial news for REGN dated on 2017-10-31: Jim Cramer Gives His Opinion On Southwest Airlines, Regeneron Pharmaceuticals And More

Financial news for REGN dated on 2017-10-31: Regeneron Reports Results From Phase 3 Study Of Dupilumab In People With Severe Steroid-Dependent Asthma: 'Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function'

Financial news for REGN dated on 2017-10-20: The Market In 5 Minutes: Tax Overhaul In Focus As Senate Passes Budget Plan

Financial news for REGN dated on 2017-10-20: Benzinga's Top Upgrades, Downgrades For October 20, 2017

Financial news for REGN dated on 2017-10-20: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for REGN dated on 2017-10-20: Barclays Downgrades Regeneron Pharmaceuticals to Underweight

Financial news for REGN dated on 2017-10-16: Sanofi and Regeneron Announce 'Positive' Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis

Financial news for REGN dated on 2017-10-05: Amgen 'Disappointed' In Court Decision To Reverse Praluent Sales Ban

Financial news for REGN dated on 2017-10-05: Regeneron PR Confirms Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent

Financial news for REGN dated on 2017-10-05: UPDATE: Amgen Highlights To Benzinga, In Process Of Lifting Ban, U.S. Appeals Court Also Rejected A Main Argument Brought By Sanofi & Regeneron; Co. States 'We look forward to reasserting our rights in court'

Financial news for REGN dated on 2017-10-05: Amgen Responds To U.S. Appeals Court Decision to Reverse District Court Ban On Sales Of Sanofi/Regnereron's Praluent, Tells Benzinga: 'We are disappointed by the Court's action,' Ability To Deliver New Medicines Depends On 'Meaningful patent protection'

Financial news for REGN dated on 2017-10-05: Regeneron Shares Halted Up 1.8% Following Earlier Report Appeals Court Has Thrown Out Ban On Sanofi, Regeneron's Praluent Brought By Amgen

Financial news for REGN dated on 2017-10-05: UPDATE: Court Filing Confirms Earlier Rumor Of Sanofi Winning New Trial vs Amgen In Case Over Praluent

Financial news for REGN dated on 2017-10-05: Regeneron Shares Halted News Pending

Financial news for REGN dated on 2017-10-05: Hearing Sanofi Wins New Trial In Amgen Case Over Praluent

Financial news for REGN dated on 2017-10-02: Regeneron Reports New Partnerships with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens

Financial news for REGN dated on 2017-09-28: Regeneron, Sanofi Announce Approval of DUPIXENT in EU to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis

Financial news for REGN dated on 2017-09-17: Sanofi, Regeneron Announce Positive Study Results for Dupixent in Patients With Moderate-to-Severe Atopic Dermatitis

Financial news for REGN dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for REGN dated on 2017-09-11: 12 Biggest Mid-Day Losers For Monday

Financial news for REGN dated on 2017-09-11: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for REGN dated on 2017-09-11: Regeneron, Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma

Financial news for REGN dated on 2017-09-08: Regeneron, Sanofi Announce FDA Breakthrough Therapy Designation for Cemiplimab (REGN2810) for for Advanced Cutaneous Squamous Cell Carcinoma

Financial news for REGN dated on 2017-09-01: The Pullback In Sanofi Is A Buying

Opportunity, Says Argus

Financial news for REGN dated on 2017-08-17: Benzinga's Top Upgrades, Downgrades For August 17, 2017

Financial news for REGN dated on 2017-08-17: Evercore ISI Group Initiates Coverage On Regeneron Pharmaceuticals with Outperform Rating, Announces \$605.00 Price Target

Financial news for REGN dated on 2017-08-14: Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus, Suptavumab Didn't Show Signs Of Efficacy In A Subgroup Of Patients

Financial news for REGN dated on 2017-08-14: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for REGN dated on 2017-08-07: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for REGN dated on 2017-08-03: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for REGN dated on 2017-08-03: Regeneron Sees FY17 EYLEA US Net Product Sales Growth ~10% YoY

Financial news for REGN dated on 2017-08-03: Regeneron Reports Q2 Adj. EPS \$4.17 vs \$3.17 Est., Sales \$1.47B vs \$1.35B Est.

Financial news for REGN dated on 2017-08-03: Earnings Scheduled For August 3, 2017

Financial news for REGN dated on 2017-08-01: Expectations For Regeneron No Longer Realistic; Analyst Downgrades

Financial news for REGN dated on 2017-08-01: Benzinga's Top Upgrades, Downgrades For August 1, 2017

Financial news for REGN dated on 2017-08-01: The Market In 5 Minutes

Financial news for REGN dated on 2017-08-01: Baird Downgrades Regeneron Pharmaceuticals to Underperform

Financial news for REGN dated on 2017-08-01: Baird Downgrades Regeneron to Underperform from Neutral

Financial news for REGN dated on 2017-07-31: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for REGN dated on 2017-07-21: Regeneron, Sanofi Report Received Positive CHMP Opinion For Dupixent To Treat Adult Patients With Moderate-To-Severe Atopic Dermatitis

Financial news for REGN dated on 2017-07-21: Sanofi and Regeneron's Dupixent for Severe Eczema Recommended for Approval by the EU Medicines Agency

Financial news for REGN dated on 2017-07-20: Lightning Round: Jim Cramer Shares His Thoughts On GameStop, Pfizer And More

Financial news for REGN dated on 2017-06-27: Regeneron, Sanofi Announce EU Approval of Kevzara to Treat Adult Patients with Moderately to Severely Active RA

Financial news for REGN dated on 2017-06-26: Is It Time To Step To The Sidelines On Regeneron?

Financial news for REGN dated on 2017-06-26: Benzinga's Top Upgrades, Downgrades For June 26, 2017

Financial news for REGN dated on 2017-06-26: Bernstein Downgrades Regeneron Pharmaceuticals to Market Perform

Financial news for REGN dated on 2017-06-23: Mid-Day Market Update: Bed Bath & Beyond Drops Following Disappointing Earnings; Synchronoss Technologies Shares Surge

Financial news for REGN dated on 2017-06-23: Mid-Morning Market Update: Markets Mostly Flat; BlackBerry Sales Miss Views

Financial news for REGN dated on 2017-06-22: Regeneron Provides Deal Details On Royalty Agreement With Novartis For ACZ885

Financial news for REGN dated on 2017-06-22: Raymond James Raises Regeneron Price Target From \$475 to \$547

Financial news for REGN dated on 2017-06-20: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for REGN dated on 2017-06-15: Regeneron Lower Day After 8-K Filing, Increased Competition For Pain Remedy

Financial news for REGN dated on 2017-06-11: Sanofi, Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent in Individuals with Diabetes and Hypercholesterolemia

Financial news for REGN dated on 2017-06-08: Watch Regeneron, AbbVie and OncoSec as FDA Shows Orphan Status Granted

Financial news for REGN dated on 2017-06-04: Sanofi, Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 #ASCO17

Financial news for REGN dated on 2017-05-25: Diplomat Pharmacy Announces It Will Dispense Regeneron's KEVZARA

Financial news for REGN dated on 2017-05-25: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for REGN dated on 2017-05-24: Regeneron Announces Positive Phase 2 Data For ANGPTL3/Evinacumab, Met Primary Endpoint With No Adverse Events Leading To Discontinuation

Financial news for REGN dated on 2017-05-24: Q1 Seasonality In The Pharma/Biotech Space: What It Is, Why It Happens And Who Is Affected

Financial news for REGN dated on 2017-05-22: Regeneron and Sanofi Report FDA Approval of Kevzara for Treatment of Moderately to Severely Active RA in Adult Patients

Financial news for REGN dated on 2017-05-22: Regeneron And Sanofi Have A Near-Term FDA Catalyst

Financial news for REGN dated on 2017-05-22: REMINDER: Regneron And Sanofi Have Sarilumab FDA PDUFA Date Today

Financial news for REGN dated on 2017-05-19: Vetr Upgrade's REGN's On Price Growth Following Positive Guidance

Financial news for REGN dated on 2017-05-08: Regeneron Reports Immuno-Oncology Clinical Study with SillaJen for Combo Treatment in Kidney Cancer

Financial news for REGN dated on 2017-05-08: Regeneron Pharma and Immuno-Oncology Announces Clinical Study Agreement

Financial news for REGN dated on 2017-05-05: The Prospects For CHS-3351, Coherus' Most Underappreciated Asset

Financial news for REGN dated on 2017-05-05: Benzinga's Top Upgrades, Downgrades For May 5, 2017

Financial news for REGN dated on 2017-05-05: Canaccord Genuity Upgrades Regeneron Pharmaceuticals to Buy

Financial news for REGN dated on 2017-05-04: Regeneron Reaffirms FY17 EYLEA US Net Product Sales Growth Outlook: Single Digit Percentage Range

Financial news for REGN dated on 2017-05-04: Regeneron Reports Q1 Adj. EPS \$2.92 vs \$3.07 Est., Sales \$1.319B vs \$1.3B Est.

Financial news for REGN dated on 2017-05-02: Regeneron, Sanofi Issue Results of 'Honestly RA,' Show 80% of RA Patients Report Life-Altering Pain Daily or Multiple Times/Week Despite Treatment

Financial news for REGN dated on 2017-04-30: Alimera's Commercial Steroid Implant For Diabetic Macular Edema, Explored

Financial news for REGN dated on 2017-04-25: Regeneron, Sanofi Report FDA Approval of Once-Monthly Dosing Option for Praluent Injection

Financial news for REGN dated on 2017-04-24: Regeneron, Sanofi Receive Positive CHMP Opinion for Marketing of Kevzara to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis

Financial news for REGN dated on 2017-04-21: EMA Recommends Approval Of Sanofi And Regeneron's Kevzara For Rheumatoid Arthritis Treatment

Financial news for REGN dated on 2017-04-17: Barron's Picks And Pans: Drug Stocks, Hanesbrands, Wabtec And More

Financial news for REGN dated on 2017-04-06: Your Cheat Sheet For Q1 Biotech Earnings

Financial news for REGN dated on 2017-04-06: Regeneron Reports Evinacumab Received FDA Breakthrough Therapy Designation for HoFH

Financial news for REGN dated on 2017-03-28: Regeneron, Sanofi To Host Conference Call To Discuss Dupixent FDA Approval Today 4pm ET

Financial news for REGN dated on 2017-03-28: Regeneron's Dupixent Passes The FDA Muster; Baird Sees Strong Launch

Financial news for REGN dated on 2017-03-28: Regeneron Shares Resume Trading, Now Up 0.07%

Financial news for REGN dated on 2017-03-28: Regeneron Shares to Resume Trade at 12:05 p.m. EDT

Financial news for REGN dated on 2017-03-28: Regeneron and Sanofi Announce FDA Approval of DUPIXENT

Financial news for REGN dated on 2017-03-28: TheStreet's Adam Feuerstein Tweets '\$REGN \$SNY Dupixent approved.'

Financial news for REGN dated on 2017-03-28: TheStreet's Adam Feuerstein Tweets '\$REGN halted. Dupi approval announcement coming.'

Financial news for REGN dated on 2017-03-28: Baird Analyst Brian Skorney Tweets: '\$REGN halted. Dupixent PDUFA is tomorrow.'

Financial news for REGN dated on 2017-03-28: BZ NOTE: Regeneron Halt Related To FDA PDUFA Decision On Dupixent Tomorrow

Financial news for REGN dated on 2017-03-28: Regeneron Pharmaceuticals Halted News Pending

Financial news for REGN dated on 2017-03-27: Adam Feuerstein Tweets: Tomorrow's FDA drug approval decision will be Roche Ocrevus in MS. (Also affecting \$BIIB) Wednesday -- \$REGN \$SNY Dupixent in eczema.

Financial news for REGN dated on 2017-03-20: Esperion Therapeutics Rockets 70% Higher After Big Selloff

Financial news for REGN dated on 2017-03-20: Leerink Presents: Your 2017 Biopharma Catalyst Tracker

Financial news for REGN dated on 2017-03-17: Esperion Falls Victim To Amgen's Poor Repatha Results

Financial news for REGN dated on 2017-03-17: Amgen Shares Down 5.6%, Regeneron Shares Down 3%

Financial news for REGN dated on 2017-03-17: Watching Shares of Regeneron, Sanofi Amid Expectation for Amgen News Related to Repatha at 9 a.m. EDT

Financial news for REGN dated on 2017-03-11: Your Guide To Patent Play Exposure

Financial news for REGN dated on 2017-03-10: Vetr Downgrades Regeneron Off Of Share Rise

Financial news for REGN dated on 2017-03-09: Benzinga's Top Upgrades, Downgrades For March 9, 2017

Financial news for REGN dated on 2017-03-09: UBS Initiates Coverage On Regeneron Pharmaceuticals With Buy, Announces \$435 Price Target

Financial news for REGN dated on 2017-03-08: Here's Your March PDUFA Date Preview

Financial news for REGN dated on 2017-03-07: Regeneron, Sanofi Report Will Present New Phase 3 Praluent Injection Clinical Trial Analyses at ACC.17 Scientific Sessions

Financial news for REGN dated on 2017-03-05: Regeneron, Sanofi Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DUPIXENT in Moderate-to-Severe Atopic Dermatitis

Financial news for REGN dated on 2017-03-04: Icahn's (Potential) Move Into Biotech

Financial news for REGN dated on 2017-03-01: Adverum Biotechnologies Reports Regeneron Pharma Extends Research Term Of Partnership, Licensing Deal Through May 2020

Financial news for REGN dated on 2017-02-24: The Most Overpaid CEOs In S&P 500 Companies That Largely Underperformed The Market

Financial news for REGN dated on 2017-02-13: Benzinga's Top Upgrades, Downgrades For February 13, 2017

Financial news for REGN dated on 2017-02-13: The Market In 5 Minutes: Hello... Can You Hear Me?

Financial news for REGN dated on 2017-02-13: PiperJaffray Upgrades Regeneron Pharmaceuticals To Overweight

Financial news for REGN dated on 2017-02-09: Stay Of Court Injunction A Mild Positive For Regeneron

Financial news for REGN dated on 2017-02-09: Q4 2016 Real-Time Call Brief

Financial news for REGN dated on 2017-02-09: Regeneron Gets 'Encouraging' Judicial Decision, Could Still Lose Appeal

Financial news for REGN dated on 2017-02-09: Regeneron Spikes to High of \$366.95 on Volume

Financial news for REGN dated on 2017-02-09: Regeneron Says Changes In Pharmaceutical Drug Pricing Will Need Congressional Action

Financial news for REGN dated on 2017-02-09: Regeneron Sees FY17 EYLEA US Net Product Sales Up in the Single-Digit Percentage Range vs 2016

Financial news for REGN dated on 2017-02-09: Regeneron Reports Q4 Adj. EPS \$3.04 vs \$3.03 Est., Sales \$1.227B vs \$1.3B Est.

Financial news for REGN dated on 2017-02-09: Earnings Scheduled For February 9, 2017

Financial news for REGN dated on 2017-02-08: Regeneron and Sanofi PR Confirms Reports Appeals Court Grants Stay of Permanent Injunction for Praluent During Appeals Process, Drug Continues To Be Available To Patients In U.S.

Financial news for REGN dated on 2017-02-08: UPDATE: Court of Appeals in Regeneron, Sanofi, Amgen Case Related to Praluent Issued Order Granting Emergency Motion to Stay Pending Appeal

Financial news for REGN dated on 2017-02-08: Hearing Sanofi, Regeneron Won Order Allow Praluent Sales to Continue

Financial news for REGN dated on 2017-02-08: Regeneron Shares Closed Down 1%, Saw After-Hours Action Ahead of Halt; BZ NOTE: Co. Was Expected to Host Q4 Earnings Conference Call Thurs. Morning Before the Open

Financial news for REGN dated on 2017-02-08: Regeneron Shares Halted News Pending

Financial news for REGN dated on 2017-02-01: Regeneron, Sanofi Announce First Approval of Kevzara for Treatment of Moderately to Severely Active RA in Adults by Health Canada

Financial news for REGN dated on 2017-01-13: Form 4 Shows Sanofi Buys 87,298 Shares Of Regeneron Pharmaceutical

Financial news for REGN dated on 2017-01-11: Top 10 S&P Stocks Of The Obama Presidency

Financial news for REGN dated on 2017-01-10: Catalyst Alert: Amgen/Regeneron Patent Case Appeal Could Be Decided By April

Financial news for REGN dated on 2017-01-09: 8-K from Regeneron Shows Prelim. US Net Sales of EYLEA Injection \$858M in Q4, \$3.32B in FY16, Global Sales of EYLEA \$5B+ for FY16

Financial news for REGN dated on 2017-01-09: Why The Amgen/Regeneron Patent Saga Is Far From Over

Financial news for REGN dated on 2017-01-09: Legal Experts Weigh In On The Amgen/Regeneron Patent Case

Financial news for REGN dated on 2017-01-06: 15 Biggest Mid-Day Losers For Friday

Financial news for REGN dated on 2017-01-06: Low Odds Court Ruling Against Regeneron Get Reversed On Appeal

Financial news for REGN dated on 2017-01-06: Amgen Higher After Favorable Court Ruling

Financial news for REGN dated on 2017-01-06: 5 Key Takeaways In Regeneron's Praluent Suit, Steps Forward

Financial news for REGN dated on 2017-01-06: Regeneron Falls As Court Grants Permanent Injunction For Infringement Of Amgen's Repatha Patents

Financial news for REGN dated on 2017-01-06: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for REGN dated on 2017-01-06: Regeneron Down 7% Following Trade Resumption

Financial news for REGN dated on 2017-01-06: UPDATE: Court Grants Permanent Injunction for Infringement of Amgen's Repatha Patents

Financial news for REGN dated on 2017-01-05: Amgen Wins Ban On Sanofi's Sales Of Praluent Cholesterol Drug

Financial news for REGN dated on 2017-01-05: Regeneron Shares Halted News Pending

Financial news for REGN dated on 2017-01-03: Regeneron, Sanofi Shares Indicated Lower, Amgen Shares Higher as Hearing Bid to Overturn Amgen's Win in Cholesterol Drug Patent Case Was Lost

Financial news for REGN dated on 2017-01-03: Regeneron Spikes to High of \$383.09 on Volume

Financial news for REGN dated on 2016-12-27: Regeneron Eyes A Comeback In 2017

Financial news for REGN dated on 2016-12-20: BMO Capital Initiates Coverage On Regeneron Pharmaceuticals at Market Perform, Announces \$419.00 Target

Financial news for REGN dated on 2016-12-16: Ophthotech Clinical Failure Spurs Massive Layoffs; Stock Rises

Financial news for REGN dated on 2016-12-16: Nesvacumab Key Catalyst For Regeneron In 2017; BTIG Upgrades To Buy

Financial news for REGN dated on 2016-12-16: Benzinga's Top Upgrades, Downgrades For December 16, 2016

Financial news for REGN dated on 2016-12-16: BTIG Research Upgrades Regeneron Pharmaceuticals to Buy, Announces \$460.00 Target

Financial news for REGN dated on 2016-12-14: Which Wet AMD Stock Would You Buy Right Now?

Financial news for REGN dated on 2016-12-13: What Fovista's Fail Means For OHR Pharma

Financial news for REGN dated on 2016-12-12: 18 Biggest Mid-Day Gainers For Monday

Financial news for REGN dated on 2016-12-12: One Way To Look At The Ophthotech-Regeneron Pair Trade

Financial news for REGN dated on 2016-12-12: The Market In 5 Minutes: Oil Gushes Higher

Financial news for REGN dated on 2016-12-12: Immune Pharmaceuticals CEO Talks Company And Its Recent Market Rally

Financial news for REGN dated on 2016-12-12: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for REGN dated on 2016-12-12: Chardan Upgrades Regeneron; Cites Fovista Failure, Stock's Recent Underperformance

Financial news for REGN dated on 2016-12-12: Chardan Capital Upgrades Regeneron Pharmaceuticals to Neutral, Raises Target to \$350.00

Financial news for REGN dated on 2016-12-08: Biotech Stocks Convalescing After Wednesday's Trump-Inspired Biotech Selloff

Financial news for REGN dated on 2016-12-08: Regeneron, Sanofi Announce Marketing Authorization Application for Dupixent Accepted for Review by EMA

Financial news for REGN dated on 2016-12-07: Pfizer, J&J, Other Big Pharma Names Dip Lower Just After the Open

Financial news for REGN dated on 2016-12-02: Stifel Remains Buyers Of Ophthotech As Year-End Binary Event Looms

Financial news for REGN dated on 2016-12-01: RAPS Organization Editor Zach Brennan Tweets: \$REGN CEO: The real reason we're not liked: We've used price increases to cover up the gaps in innovation. That's just a fact.

Financial news for REGN dated on 2016-12-01: Forbes Healthcare Summit Concludes Today; Presenters Include Express Scripts, Allergan, IBM, Bristol-Myers Squibb, Merck, Anthem, Eli Lilly, And Regeneron

Financial news for REGN dated on 2016-11-30: 2 Possible Scenarios For Ophthotech

Financial news for REGN dated on 2016-11-21: Vetr Thinks Regeneron Is Looking Healthy

Financial news for REGN dated on 2016-11-17: Mid-Morning Market Update: Markets Edge Higher; Wal-Mart Posts Mixed Q3 Results

Financial news for REGN dated on 2016-11-14: Datamonitor Healthcare Analyst Kevin Shannon Tweets: \$REGN evinacumab lowers triglycerides by up to 70% with no serious AEs. However, slight increase in moderate AEs (mostly headaches) #AHA16

Financial news for REGN dated on 2016-11-14: Regeneron Shares Spiking To High Of \$452.96, Now Coming Back To \$444 Level

Financial news for REGN dated on 2016-11-14: 10 Stocks That Rallied Four Days, Then Sold Off On Friday

Financial news for REGN dated on 2016-11-09: Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%

Financial news for REGN dated on 2016-11-04: A Peek Into The Markets: U.S. Stock Futures Edge Lower; All Eyes On Jobs Report

Financial news for REGN dated on 2016-11-04: Regeneron's Q3 Results Mixed Compared To Analyst Estimates

Financial news for REGN dated on 2016-11-04: Regeneron Pharma Reports Q3 Adj. EPS \$3.13 vs \$2.71 Est., Sales \$1.22B vs \$1.29B Est.

Financial news for REGN dated on 2016-11-04: Earnings Scheduled For November 4, 2016

Financial news for REGN dated on 2016-10-28: Regeneron Pharma Shares Resume Trade, Now Down 2.5%

Financial news for REGN dated on 2016-10-28: Regeneron Shares to Resume Trade at 3:05 p.m. EDT

Financial news for REGN dated on 2016-10-28: BZ NOTE: Regeneron Disclosed In Press Release Earlier That Sanofi Was In Discussions With The FDA Regarding Deficiencies In Its French Facility, The Street's Adam Feuerstein Highlights This In A Recent Tweet

Financial news for REGN dated on 2016-10-28: UPDATE: Sanofi Says Co., Regeneron Remain Committed to Development of Sarilumab

Financial news for REGN dated on 2016-10-28: Regeneron And Sanofi Receive Complete Response Letter From FDA; Refers To Certain Deficiencies In Mfg Practice At Sanofi Facility; Satisfactory Resolution Of These Deficiencies Is Required Before The FDA Will Grant Approval For Sarilumab

Financial news for REGN dated on 2016-10-28: BZ NOTE: Regeneron Shares Likely Halted Ahead of PDUFA Date for Sanilumab for Treatment of RA

Financial news for REGN dated on 2016-10-28: Regeneron Pharma Shares Halted News Pending

Financial news for REGN dated on 2016-10-28: Regeneron Says Advised By Collaborator, Sanofi, That Manufacturing Deficiencies have been Raised by FDA During Inspection of Sanofi Facility

Financial news for REGN dated on 2016-10-17: News Of Clinical Hold For Fasinumab Weighs On Regeneron, Teva Shares

Financial news for REGN dated on 2016-10-17: Regeneron and Teva Place Phase 2b Study On Chronic Back Pain on Clinical Hold

Financial news for REGN dated on 2016-10-13: Deal With Regeneron Means Validation For Ocular Therapeutix

Financial news for REGN dated on 2016-10-13: Mid-Afternoon Market Update: Lindsay Gains Following Q4 Results; Fluidigm Shares Drop

Financial news for REGN dated on 2016-10-13: 10 Biggest Mid-Day Gainers For Thursday

Financial news for REGN dated on 2016-10-13: Mid-Day Market Update: Ocular Therapeutix Surges Following Collaboration Deal With Regeneron; Flex Pharma Shares Slide

Financial news for REGN dated on 2016-10-13: Mid-Morning Market Update: Markets Open Lower; Delta Air Lines Profit Beats Estimates

Financial news for REGN dated on 2016-10-13: Ocular Therapeutix Shares Charge Higher Following Collaboration Deal With Regeneron

Financial news for REGN dated on 2016-10-13: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for REGN dated on 2016-10-13: UPDATE: Ocular Therapeutix Will Receive up to \$305M in Milestone Payments in Addition to Royalties on Potential Future Net Sales

Financial news for REGN dated on 2016-10-13: Ocular Therapeutix, Regeneron Report Entering Into of Strategic Collaboration for Developing Sustained Release Formulation of Aflibercept for Treatment of Wet AMD, Other Serious Retinal Diseases

Financial news for REGN dated on 2016-10-10: Option Alert: REGN Jan17 450 Calls Sweep: 502 @ ASK \$10.50: 512 traded vs 223 OI: Earnings 11/2 \$394.91 Ref

Financial news for REGN dated on 2016-10-03: Hard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista

Financial news for REGN dated on 2016-09-30: Chardan Rates Regeneron A Sell, Advises Caution

Financial news for REGN dated on 2016-09-30: 12 Biggest Mid-Day Losers For Friday

Financial news for REGN dated on 2016-09-30: Traders Currently Passing Around Earlier Pre-Open Comment from Chardan Analyst on Ophthotech, Regeneron: Expectation for 'a limited read-across from the REGN2176-3 data to Fovista's pivotal phase III readout'

Financial news for REGN dated on 2016-09-30: Here's Why Ophthotech Is Trading Down On Regeneron's News

Financial news for REGN dated on 2016-09-30: Spokesperson For Ophthotech Says Company Has, "No Comment At This Time" Regarding Stock Selloff In Sympathy To Regeneron's anti-PDGFR Study Fail

Financial news for REGN dated on 2016-09-30: The Street's Adam Feuerstein Tweets: \$OPHT -10% on \$REGN anti-PDGFR study fail.

Financial news for REGN dated on 2016-09-30: Adam Feuerstein @adamfeuerstein Tweet: \$OPHT -10% on \$REGN anti-PDGFR study fail.

Financial news for REGN dated on 2016-09-30: Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration

Financial news for REGN dated on 2016-09-27: The Drug Price Increase Debate: Separating The Winners From The Losers

Financial news for REGN dated on 2016-09-26: Regeneron, Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by FDA

Financial news for REGN dated on 2016-09-20: Regeneron, Teva Reports Global Collaboration to Develop and Commercialize Fasinumab

Financial news for REGN dated on 2016-08-29: Regeneron, Sanofi Present Positive Phase 3 Investigational Data for Praluent Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016

Financial news for REGN dated on 2016-08-22: Regeneron Reports Deal with BARD for Manufacturing, Testing of New Antibodies Against MERS Virus

Financial news for REGN dated on 2016-08-08: Q2 Earnings Report Card: Biotech

Financial news for REGN dated on 2016-08-05: Benzinga's Top Downgrades

Financial news for REGN dated on 2016-08-05: The Market In 5 Minutes: Blowout Jobs Report Pushes Markets Higher

Financial news for REGN dated on 2016-08-05: Baird Downgrades Regeneron Pharmaceuticals to Neutral

Financial news for REGN dated on 2016-08-04: Thursday Morning's Top Earnings Reports

Financial news for REGN dated on 2016-08-04: The Market In 5 Minutes: Bank Of England Cut Interest Rates For The First Time In 7 Years

Financial news for REGN dated on 2016-08-04: Regeneron Reaffirms FY16 EYLEA US Product Sales Growth 20-25% YoY

Financial news for REGN dated on 2016-08-04: Regeneron Reports Q2 Adj. EPS \$2.82 vs \$2.65 Est., Sales \$1.213B vs \$1.24B Est.

Financial news for REGN dated on 2016-08-04: Earnings Scheduled For August 4, 2016

Financial news for REGN dated on 2016-08-03: Regeneron To Post Double-Digit Returns, Vetr Crowd Says

Financial news for REGN dated on 2016-08-02: Regeneron, Adicet Bio Report Strategic Partnership to Discover and Develop Next-Generation Engineered Immune Cell Therapeutics

Financial news for REGN dated on 2016-08-01: Sanofi, Regeneron Announce EMA Acceptance for Review of Marketing Authorisation Application for Sarilumab

Financial news for REGN dated on 2016-07-28: Watch These 10 Huge Put Purchases In Thursday Trade

Financial news for REGN dated on 2016-07-27: Option Alert: REGN Aug16 412.5 Puts: 535 @ ASK \$15.20: 552 traded vs 0 OI: Earnings 8/4 Before Open \$409.86 Ref

Financial news for REGN dated on 2016-07-27: Option Alert: REGN Aug16 410 Puts Sweep: 548 @ ASK \$15.60: 558 traded vs 51 OI: Earnings 8/4 Before Open \$407.06 Ref

Financial news for REGN dated on 2016-07-18: Option Alert: REGN Aug16 340 Puts Sweep: 757 @ ASK \$4.60: 769 traded vs 274 OI: Earnings 8/4 Before Open \$377.53 Ref

Financial news for REGN dated on 2016-07-05: Regeneron, Sanofi Announce Approval of Praluent for Treatment of Hypercholesterolemia in Japan

Financial news for REGN dated on 2016-06-29: Regeneron Is 'One Of The Stronger Growers In Biotech'

Financial news for REGN dated on 2016-06-29: Bernstein Initiates Coverage on Regeneron Pharmaceuticals at Outperform

Financial news for REGN dated on 2016-06-23: Regeneron CEO And CFO Met With Citi: Here Are The Takeaways

Financial news for REGN dated on 2016-06-20: 5 Of The Hottest Stocks To Own During The Summer

Financial news for REGN dated on 2016-06-20: Watch These 5 Huge Put Purchases In Monday Trade

Financial news for REGN dated on 2016-06-17: Option Alert: REGN Jul16 345 Puts: 949 @ ASK \$8.70: 1003 traded vs 55 OI: Earnings 8/2 \$360.20 Ref

Financial news for REGN dated on 2016-06-13: Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators

Financial news for REGN dated on 2016-06-10: Vetr Crowd: After A Large Decline, Regeneron Could Surge 15.5%

Financial news for REGN dated on 2016-06-09: Bernstein Lists Active Buyers Of Ophthalmology Companies

Financial news for REGN dated on 2016-06-09: Regeneron Vol Spike

Financial news for REGN dated on 2016-06-06: Regeneron, Sanofi Announce that Dupilumab Used with Topical Corticosteroids was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients

Financial news for REGN dated on 2016-06-01: Regeneron Rallies Off Favorable Interim Data From Evinacumab Trial

Financial news for REGN dated on 2016-05-31: Regeneron Presents Favorable Interim Data From Stage 2 Proof-Of-Concept Trial Of Evinacumab

Financial news for REGN dated on 2016-05-31: Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

Financial news for REGN dated on 2016-05-26: CEOs Vs. Hedge Fund Managers: Who Gets Paid Better?

Financial news for REGN dated on 2016-05-17: Has A Biotech Recovery Started Yet?

Financial news for REGN dated on 2016-05-16: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for REGN dated on 2016-05-16: Regeneron +7.3% Premarket; Temasek Increases Stake to 126,351 Shares vs 58,289 Previous

Financial news for REGN dated on 2016-05-14: Barron's Picks And Pans: Regeneron, Axalta, Alleghany And More

Financial news for REGN dated on 2016-05-11: Regeneron Says They've Signed Deals With Other Payers In Addition To Cigna, To Assess Value Of Its Praluent Cholesterol Drug

Financial news for REGN dated on 2016-05-05: Regeneron Gains 4% Following Q1 Earnings Release

Financial news for REGN dated on 2016-05-05: 12 Stocks Moving In Thursday's Pre-Market Session

Financial news for REGN dated on 2016-05-05: Regeneron Q1 EPS \$2.57 vs \$2.58 est, Revenue \$1.2B vs \$1.2B est

Financial news for REGN dated on 2016-05-05: Earnings Scheduled For May 5, 2016

Financial news for REGN dated on 2016-05-02: Chardan Views Regeneron Fasinumab Data As Net Negative, Reiterates Sell

Financial news for REGN dated on 2016-05-02: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain, Showed Significant Improvement In Primary Endpoint & Improvements In Secondary Endpoint

Financial news for REGN dated on 2016-04-20: Wells Fargo Downgrades Regeneron Pharmaceuticals to Market Perform

Financial news for REGN dated on 2016-04-11: Regeneron and Intellia Therapeutics Collaborate to Discover and Develop CRISPR/Cas Therapeutics

Financial news for REGN dated on 2016-04-04: Roth Capital Maintains Buy on Regeneron Pharmaceuticals, Lowers PT to \$520.00

Financial news for REGN dated on 2016-04-04: Leerink Swann Maintains Outperform on Regeneron Pharmaceuticals, Raises PT to \$523.00

Financial news for REGN dated on 2016-04-01: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for REGN dated on 2016-04-01: Mid-Afternoon Market Update: Crude Oil Down 3.5%; Tesla Shares Rise Following Model 3 Launch

Financial news for REGN dated on 2016-04-01: Benzinga's Volume Movers

Financial news for REGN dated on 2016-04-01: 10 Stocks Moving In Friday's Pre-Market Session

Financial news for REGN dated on 2016-04-01: Regeneron +4% Premarket @ \$376; Co Announced Positive Results from Atopic Dermatitis Trials

Financial news for REGN dated on 2016-04-01: Regeneron, Sanofi Announce Positive

Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients

Financial news for REGN dated on 2016-03-31: Worst Stocks Of The First Quarter

Financial news for REGN dated on 2016-03-24: Regeneron Reports Joint Development with Bayer for Novel Combo Therapy for Eye Diseases

Financial news for REGN dated on 2016-03-23: Cramer Shares His Thoughts On Lockheed Martin, Celgene And Regeneron

Financial news for REGN dated on 2016-03-23: Regeneron, Sanofi Announce Positive Topline Results from Phase 3 Praluent Study in Patients Undergoing LDL Apheresis Therapy

Financial news for REGN dated on 2016-03-21: Why Regeneron's Praluent Is Likely To Be Removed From The U.S. Market This Year

Financial news for REGN dated on 2016-03-17: The Market In 5 Minutes: Thursday, March 17, 2016

Financial news for REGN dated on 2016-03-17: Goldman Sachs Considers Implications For Regeneron, Amgen, Sanofi Following PCSK9 Ruling

Financial news for REGN dated on 2016-03-16: Chardan Downgrades Regeneron To Sell

Financial news for REGN dated on 2016-03-16: The Plot Thickens At Amgen; Piper Still Overweight

Financial news for REGN dated on 2016-03-16: Jury In Repatha Patent Case Ruled In Favor Of Amgen, Against Regeneron And Sanofi

Financial news for REGN dated on 2016-03-16: UPDATE: Chardan Capital Lowers Regeneron Pharmaceuticals PT to \$325.00

Financial news for REGN dated on 2016-03-16: Chardan Capital Downgrades Regeneron Pharmaceuticals to Sell

Financial news for REGN dated on 2016-03-16: Piper Jaffray Says Street Downplaying What Regeneron And Sanofi Owe Amgen, May Be Substantially Higher Than Street Expectations Without Treble Damages or Willful Infringement

Financial news for REGN dated on 2016-03-16: Amgen Wins Patent Case On Repatha

Financial news for REGN dated on 2016-03-16: Regeneron Shares Resume Trade, Turn Negative, Now Down ~1%

Financial news for REGN dated on 2016-03-16: Amgen's Rally Off Positive Verdict In Patent Case Fades

Financial news for REGN dated on 2016-03-16: Regeneron to Resume Trading at 1:00 PM ET

Financial news for REGN dated on 2016-03-16: UPDATE: Regeneron, Sanofi Say Ongoing Litigation Does Not Impact Praluent Injection

Financial news for REGN dated on 2016-03-16: UPDATE: Regeneron, Sanofi Say Jury Verdict Asserted Claims of Two Amgen Patents for Antibodies Targeting PCSK9 as Valid

Financial news for REGN dated on 2016-03-16: Regeneron, Sanofi Issue Release Saying 'Strongly Disagree' with US Jury Verdict in Ongoing Patent Litigation Related to Praluent, Will Appeal

Financial news for REGN dated on 2016-03-16: Jefferies Says SNY/REGN Had A Win Today When Judge Robinson Determined SNY/REGN Praluent Infringes And Ruled Co's Are Liable For Damages And Royalties To AMGN

Financial news for REGN dated on 2016-03-16: Hearing Judge in Repatha Case Has Said Issue of Defendants' Alleged Infringement Will Not Be Heard by Jury

Financial news for REGN dated on 2016-03-16: Wild Price Action in Amgen Shares Implies Some Trader Confusion on Report of Ruling in Repatha Patent Case; Stock Spiked to High of \$147, Came Back Down to Below \$144 Shortly After

Financial news for REGN dated on 2016-03-16: Hearing Federal Judge Has Issued Ruling Against Amgen, Said Co. Has Not Shown Clear, Convincing Evidence Defendant's Invalidity Defenses Were Objectively Baseless

Financial news for REGN dated on 2016-03-16: Spike Higher in Amgen Ahead of Verdict

for Repatha Patent Case Likely Indicates Loss for Regeneron

Financial news for REGN dated on 2016-03-16: Adam Feuerstein @adamfeuerstein Tweet: Jury ruled in favor of \$AMGN, against \$REGN \$SNY in PCSK9 patent case, according to Mark Schoenebaum.

Financial news for REGN dated on 2016-03-16: Amgen Spikes to High of \$145.30; Hearing Jury Verdict

Financial news for REGN dated on 2016-03-16: Regeneron Shares Halted News Pending

Financial news for REGN dated on 2016-03-15: Benzinga's Top Initiations

Financial news for REGN dated on 2016-03-15: Gabelli & Co Initiates Coverage on Regeneron Pharmaceuticals at Buy

Financial news for REGN dated on 2016-03-14: UPDATE: Hearing Jefferies Has Highlighted Decision by Judge Moving Forward Jury in Regeneron/Sanofi/Amgen Case Would Not Consider One of Three Defense Arguments Proposed as for Invalidiation

Financial news for REGN dated on 2016-03-14: Regeneron Shares Pullback Following Cautious Comments from Jefferies

Financial news for REGN dated on 2016-03-11: Regeneron Says Phase 3 Monotherapy Study Met Primary Endpoint Demonstrating That Sarilumab Was Superior To Adalimumab

Financial news for REGN dated on 2016-03-09: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for REGN dated on 2016-03-08: Brean Capital Assumes Regeneron Pharmaceuticals at Buy, Announces \$489.00 PT

Financial news for REGN dated on 2016-03-08: Brean Capital Says Regeneron Pharma Robust Pipeline Drives Upside, Calls Out Dupilumab As Next Catalyst

Financial news for REGN dated on 2016-03-03: Benzinga's Top Initiations

Financial news for REGN dated on 2016-03-03: SunTrust Robinson Humphrey Initiates Coverage on Regeneron Pharmaceuticals at Neutral, Announces \$450.00 PT

Financial news for REGN dated on 2016-03-02: Regeneron Genetics Center Publication in New England Journal of Medicine Links ANGPTL4 Inhibition and Risk of Coronary Artery Disease

Financial news for REGN dated on 2016-02-29: First Solar, GameStop, Chipotle Lead List Of March's Best Performers Over Past Decade

Financial news for REGN dated on 2016-02-25: Citi: Buy Celgene, Gilead, Biogen And Regeneron As Biotechs Recover

Financial news for REGN dated on 2016-02-25: Citigroup Initiates Coverage on Regeneron Pharmaceuticals at Buy

Financial news for REGN dated on 2016-02-22: Prospect Capital, Regeneron Lead List Of Key Insider Trades

Financial news for REGN dated on 2016-02-16: Benzinga's Top Upgrades

Financial news for REGN dated on 2016-02-16: Chardan Upgrades Regeneron Amid Relative Underperformance To Amgen Shares

Financial news for REGN dated on 2016-02-16: RBC Capital Positive On Regeneron, Expects Share Price Appreciation, Says Atopic Dermatitis Is Blockbuster Indication

Financial news for REGN dated on 2016-02-16: Chardan Remains Cautious On REGN In Midst Of Upgrade

Financial news for REGN dated on 2016-02-16: Chardan Capital Upgrades Regeneron Pharmaceuticals to Neutral, Lowers PT to \$375.00

Financial news for REGN dated on 2016-02-10: Chardan: Sell Regeneron After Sanofi Drops Patent Infringement Bombshell

Financial news for REGN dated on 2016-02-10: JP Morgan Maintains Neutral on Regeneron Pharmaceuticals, Lowers PT to \$477.00

Financial news for REGN dated on 2016-02-10: Chardan Believes Sanofi/Regeneron Invalidiation Of Amgen Patents In Entirety Is Unlikely

Financial news for REGN dated on 2016-02-10: Morgan Stanley Maintains Equal-weight on Regeneron Pharmaceuticals, Lowers PT to \$436.00, Says Dupilumab PhIII Is Next Major Catalyst

Financial news for REGN dated on 2016-02-10: UBS Maintains Buy on Regeneron Pharmaceuticals, Lowers PT to \$575.00

Financial news for REGN dated on 2016-02-10: Brean Capital Maintains Buy on Regeneron Pharmaceuticals, Lowers PT to \$489.00

Financial news for REGN dated on 2016-02-10: Barclays Maintains Equal-weight on Regeneron Pharmaceuticals, Lowers PT to \$425.00

Financial news for REGN dated on 2016-02-09: 10 Stocks Moving In Tuesday's Pre-Market Session

Financial news for REGN dated on 2016-02-09: Regeneron Pharmaceuticals Loses 7% Following Q4 Miss

Financial news for REGN dated on 2016-02-09: Regeneron Q4 EPS \$2.83 vs \$3.36 est, Revenue \$1.16B vs \$1.17B est

Financial news for REGN dated on 2016-02-09: Earnings Scheduled For February 9, 2016

Financial news for REGN dated on 2016-02-05: Leerink Is Back On Board The Biotech Train

Financial news for REGN dated on 2016-02-05: Leerink Swann Initiates Coverage on Regeneron Pharmaceuticals at Outperform

Financial news for REGN dated on 2016-01-27: Canaccord Genuity Downgrades Regeneron Pharmaceuticals to Hold

Financial news for REGN dated on 2016-01-26: Here Are The Most Notable Insider Transactions Hitting The Market

Financial news for REGN dated on 2016-01-25: Benzinga's Top Downgrades

Financial news for REGN dated on 2016-01-25: Regeneron Is Now A Sell For Chardan

Financial news for REGN dated on 2016-01-25: Chardan Capital Downgrades REGN To Sell On Infringement Evidence Related To AMGN's PCSK9 Patentts, Expects Market To Increase Focus on 'Praluent' Patent As Driver Of Share Price

Financial news for REGN dated on 2016-01-25: Chardan Capital Downgrades Regeneron Pharmaceuticals to Sell, Lowers PT to \$400.00

Financial news for REGN dated on 2016-01-21: Looking To Healthcare ETFs For Earnings Growth

Financial news for REGN dated on 2016-01-20: Credit Suisse Bullish On Most Big Pharma Names

Financial news for REGN dated on 2016-01-20: Credit Suisse Initiates REGN At Neutral, Positive On Co's Platform, Shares 'look fairly valued'

Financial news for REGN dated on 2016-01-19: Credit Suisse Initiates Coverage on Regeneron Pharmaceuticals at Neutral, Announces \$552.00 PT

Financial news for REGN dated on 2016-01-19: Roth Capital Upgrades Regeneron Pharmaceuticals to Buy

Financial news for REGN dated on 2016-01-12: Regeneron Pharma Full Year Eylea Sales over \$4B

Financial news for REGN dated on 2016-01-08: Regeneron, Sanofi Announce FDA Has Accepted For Review BLA For Sarilumab

Financial news for REGN dated on 2016-01-08: U.S. Stock Futures Surge After Jobs Data; El-Erian To Discuss Economic Situation

Financial news for REGN dated on 2016-01-08: Regeneron, Sanofi Announce Sarilumab Biologics License Application Accepted for Review FDA

Financial news for REGN dated on 2016-01-07: BTIG Research Initiates Coverage on Regeneron Pharmaceuticals at Neutral

Financial news for REGN dated on 2015-12-18: Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016

Financial news for REGN dated on 2015-12-11: Regeneron, Sanofi Announce UnitedHealth Group to Provide Preferred Access Praluent Injection

Financial news for REGN dated on 2015-12-04: Wells Fargo Initiates Coverage on Regeneron Pharmaceuticals at Outperform

Financial news for REGN dated on 2015-11-24: Regeneron, Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent Injection Fully Enrolled

Financial news for REGN dated on 2015-11-16: 5 Biotechs That Can Win From Ophthalmology Innovation

Financial news for REGN dated on 2015-11-11: US Stock Futures Gain Ahead Of Macy's Earnings

Financial news for REGN dated on 2015-11-08: Regeneron, Sanofi Present Positive Results from Pivotal Phase 3 Study of Sarilumab at ACR Annual Meeting

Financial news for REGN dated on 2015-11-06: Portfolio Armor's Current Number One Stock: Activision Blizzard

Financial news for REGN dated on 2015-11-05: Sanofi, Regeneron Report Will Present Results from Phase 3 Trials at AHA Sessions '15

Financial news for REGN dated on 2015-11-04: From Conf Call: Regeneron Q4 US Eylea Sales Might Be Negatively Impacted by Changes in Inventory Levels, Holidays, Possible Bad Weather

Financial news for REGN dated on 2015-11-04: From Conf Call: Regeneron Pharmaceuticals Sees Continued Strong Physician Demand For Eylea -Reuters

Financial news for REGN dated on 2015-11-04: Regeneron Pharma Reports Q3 EPS \$3.47 Vs Est \$3.20, Sales \$1.14B Vs Est \$1.05B

Financial news for REGN dated on 2015-11-04: Earnings Scheduled For November 4, 2015

Financial news for REGN dated on 2015-11-02: NY Judge Rules Against Regeneron In Patent Case With Merus

Financial news for REGN dated on 2015-10-30: Regeneron Announces EU Approval of EYLEA(r) (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization

Financial news for REGN dated on 2015-10-27: Armored Portfolios: The Hedged Portfolio Method

Financial news for REGN dated on 2015-10-19: Cowen: In Biotech Earnings We Trust

Financial news for REGN dated on 2015-10-12: Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives

Financial news for REGN dated on 2015-10-12: Regeneron Trading Up To \$517/Share Up 2.6% Premarket On Eli Lilly Evacetrapib Development Discontinuation, Watch Regeneron Partner Sanofi

Financial news for REGN dated on 2015-10-02: Regeneron Downgraded At Morgan Stanley; Better Biotech Peer Plays Elsewhere

Financial news for REGN dated on 2015-10-02: Morgan Stanley Downgrades Regeneron Pharmaceuticals to Equal-weight

Financial news for REGN dated on 2015-10-01: Regeneron Reports Partnership with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia; Regeneron To Receive \$55M Up Front

Financial news for REGN dated on 2015-09-28: Regeneron, Sanofi Announce Approval of Praluent for Treatment of Hypercholesterolemia in EU

Financial news for REGN dated on 2015-09-24: Regeneron and Icahn School of Medicine at Mount Sinai Announce New Antibody Research Agreement

Financial news for REGN dated on 2015-09-21: Regeneron, BARDA Agree To Development Of New Antibody Treatment For Ebola

Financial news for REGN dated on 2015-09-08: Regeneron Pharmaceuticals Reboots After UBS Upgrade

Financial news for REGN dated on 2015-09-07: UBS Upgrades Regeneron Pharmaceuticals

to Buy

Financial news for REGN dated on 2015-09-01: Regeneron and Sanofi Report New Positive Praluent Phase 3 Data Presented at ESC Congress 2015

Financial news for REGN dated on 2015-08-31: Chardan Downgrades Regeneron Pharmaceuticals, Notes Valuation Concerns

Financial news for REGN dated on 2015-08-31: Benzinga's Top Downgrades

Financial news for REGN dated on 2015-08-31: Chardan Capital Downgrades Regeneron Pharmaceuticals to Neutral, Maintains \$565.00 PT

Financial news for REGN dated on 2015-08-21: In new note to subscribers, CMT Christian Tharp making bet that 15-20% correction is coming

Financial news for REGN dated on 2015-08-21: The Other Bearish Biotech ETF Is Looking Groovy, Too

Financial news for REGN dated on 2015-08-13: What Are Payors Saying About Managed Care Giants?

Financial news for REGN dated on 2015-08-07: The Historical Correlation Between Biotech Stocks And Interest Rates

Financial news for REGN dated on 2015-08-04: Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Raises T to \$593.00

Financial news for REGN dated on 2015-08-04: Brean Capital Maintains Buy on Regeneron Pharmaceuticals, Raises PT to \$659.00

Financial news for REGN dated on 2015-08-04: Evercore Breaks Down Regeneron's Q2 Report

Financial news for REGN dated on 2015-08-04: Stocks Hitting 52-Week Highs

Financial news for REGN dated on 2015-08-04: Morning Market Gainers

Financial news for REGN dated on 2015-08-04: From Conf Call: Regeneron Sasy Bulk of Eyelea Growth Coming from DME

Financial news for REGN dated on 2015-08-04: Benzinga's Top #PreMarket Gainers

Financial news for REGN dated on 2015-08-04: Regeneron Tops Q2 Estimates, Shares Surge

Financial news for REGN dated on 2015-08-04: Regeneron +4% Premarket on Solid Earnings Beat, Upbeat Guidance

Financial news for REGN dated on 2015-08-04: Regeneron Raises FY15 EYLEA Sales Growth Outlook from 30-35% Previously to 45-50% YoY

Financial news for REGN dated on 2015-08-04: Regeneron Reports Q2 Adj. EPS \$2.89 vs \$2.77 Est., Sales \$999M vs \$887.8M Est.

Financial news for REGN dated on 2015-08-04: Earnings Scheduled For August 4, 2015

Financial news for REGN dated on 2015-08-03: 5 Biotechs With Catalysts Coming This Week

Financial news for REGN dated on 2015-07-28: Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?

Financial news for REGN dated on 2015-07-28: US Stock Futures Surge Ahead Of Fed Meeting

Financial news for REGN dated on 2015-07-28: Regeneron, Sanofi Announce Immuno-Oncology Collaboration

Financial news for REGN dated on 2015-07-27: Regeneron Pharmaceuticals CEO Boasts Recently Approved Cholesterol-Lowering Drug

Financial news for REGN dated on 2015-07-24: Regeneron Shares Spiking Lower Following Volatile Trades

Financial news for REGN dated on 2015-07-24: Regeneron Sanofi Release Confirms Approval Of Praluent

Financial news for REGN dated on 2015-07-24: Regeneron Halted Pending News

Financial news for REGN dated on 2015-07-24: Regeneron, Sanofi Announce CHMP Recommends European Approval of Praluent (alirocumab) for the Treatment of Hypercholesterolemia

Financial news for REGN dated on 2015-07-09: Benzinga's Top Downgrades

Financial news for REGN dated on 2015-07-09: UBS 'Looking Elsewhere,' Says To Sell Regeneron

Financial news for REGN dated on 2015-07-09: UBS Downgrades Regeneron Pharmaceuticals to Sell

Financial news for REGN dated on 2015-06-29: Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication

Financial news for REGN dated on 2015-06-26: Regeneron Announces EYLEA Injection Approved in Japan for the Treatment of Retinal Vein Occlusion

Financial news for REGN dated on 2015-06-18: Jim Cramer Advises His Viewers On GlaxoSmithKline, American International Group, Caesars And Caesars Acquisition

Financial news for REGN dated on 2015-06-17: The Note Moving Pharma Giants Today

Financial news for REGN dated on 2015-06-16: Avalanche Biotechnologies Buried By Disappointing Data, Downgrades

Financial news for REGN dated on 2015-06-16: Avalanche Bio Downgraded At William Blair, Firm Says Phase IIb 'A Ways Away'

Financial news for REGN dated on 2015-06-15: JMP Sees A 'Negative Market Tone' In Biotechnology

Financial news for REGN dated on 2015-06-11: Why Avalanche Biotechnologies Is Coming Off A Big Day

Financial news for REGN dated on 2015-06-10: Mid-Day Market Update: Sigma Designs Surges On Upbeat Results; Boulder Brands Shares Drop

Financial news for REGN dated on 2015-06-10: Selling The News In Regeneron

Financial news for REGN dated on 2015-06-10: FDA Panel Clears Product Path For Sanofi, Regeneron Pharmaceuticals

Financial news for REGN dated on 2015-06-10: Mid-Morning Market Update: Markets Open Higher; Oxford Industries Beats Q1 Expectations

Financial news for REGN dated on 2015-06-10: Morning Market Losers

Financial news for REGN dated on 2015-06-10: Benzinga's Top #PreMarket Losers

Financial news for REGN dated on 2015-06-09: Regeneron Shares Now Down 13 After-Hours Following Resumption of Trade; FDA Panel Recommended Approval of Praluent

Financial news for REGN dated on 2015-06-09: FDA Advisory Panel Recommends Approval of Regeneron, Sanofi's Praluent

Financial news for REGN dated on 2015-06-09: Regeneron Gives Statement on Stock Halt, Cites FDA Meeting For Praluent Today

Financial news for REGN dated on 2015-06-09: Shares of Regeneron Halted, News Pending

Financial news for REGN dated on 2015-06-05: Stocks Hitting 52-Week Highs

Financial news for REGN dated on 2015-05-21: Regeneron, Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with RA

Financial news for REGN dated on 2015-05-18: Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma

Financial news for REGN dated on 2015-05-15: Credit Suisse: Regeneron Now Worth \$550/Share

Financial news for REGN dated on 2015-05-07: Regeneron Q1 EPS \$2.88 vs \$2.68 est, Revenue \$870M vs \$825M est

Financial news for REGN dated on 2015-05-07: Earnings Scheduled For May 7, 2015

Financial news for REGN dated on 2015-05-06: Credit Suisse Analysts Assume Coverage On 10 Biotech Stocks

Financial news for REGN dated on 2015-05-06: Regeneron Earnings: Small Growth Expected, Driven By Eylea

Financial news for REGN dated on 2015-05-05: Credit Suisse Assumes Regeneron Pharmaceuticals at Outperform, Announces \$400.00 PT

Financial news for REGN dated on 2015-04-22: Regeneron Bounces Higher Off Support

Financial news for REGN dated on 2015-04-02: Biotech Bubble Valuations From Sam Islay

Financial news for REGN dated on 2015-03-26: Is It Closing Time At The Biotech Bar?

Financial news for REGN dated on 2015-03-25: UPDATE: Regeneron's EYLEA Receives FDA Approval

Financial news for REGN dated on 2015-03-25: Hearing FDA Announces Approval of New Treatment for Diabetic Retinopathy by Regeneron's Eylea

Financial news for REGN dated on 2015-03-23: Regeneron Pharmaceuticals Enters Into \$750M Senior Unsecured Five-Year Revolving Credit Facility

Financial news for REGN dated on 2015-03-20: CVS Says New Cholesterol Drug Types Could Be Costly

Financial news for REGN dated on 2015-03-20: CORRECTION: Chardan Capital Initiates Coverage on Regeneron Pharmaceuticals at Buy, Announces \$560.00 PT

Financial news for REGN dated on 2015-03-15: Sanofi, Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent Published in NEJM

Financial news for REGN dated on 2015-03-15: Regeneron, Sanofi Announce Positive 18-Month Results of ODYSSEY LONG TERM Trial with Praluent Published in NEJM

Financial news for REGN dated on 2015-03-05: Regeneron Says Goldman Sachs to Reduce Remaining Number of Warrants Held by Up to 13%; Regeneron to Pay Up to \$24M for Warrants -DJ

Financial news for REGN dated on 2015-02-27: Regeneron Signs Amended Collaboration Agreement with Sanofi-Aventis; Will No Longer Be Required to Reimburse Sanofi for 50% of Development Expenses

Financial news for REGN dated on 2015-02-26: UPDATE: Regeneron's EYLEA Injection Receives EU Approval

Financial news for REGN dated on 2015-02-26: Regeneron's EYLEA Injection Receives EU Approval

Financial news for REGN dated on 2015-02-17: Benzinga's Top Initiations

Financial news for REGN dated on 2015-02-17: Bernstein Initiates Regeneron Pharmaceuticals At Outperform

Financial news for REGN dated on 2015-02-17: Bernstein Initiates Coverage on Regeneron Pharmaceuticals at Outperform, Announces \$475.00 PT

Financial news for REGN dated on 2015-02-11: Regeneron's Expanded Pipeline Not A Concern For Morgan Stanley

Financial news for REGN dated on 2015-02-10: Piper Jaffray Downgrades Regeneron Pharmaceuticals to Neutral

Financial news for REGN dated on 2015-02-10: UPDATE: Regeneron Pharmaceuticals Posts Downbeat Q4 Earnings, But Sales Top Views

Financial news for REGN dated on 2015-02-10: Regeneron Pharma Reports Q4 EPS \$2.79 Vs Est \$2.82, Sales \$802M Vs Est \$781.52M

Financial news for REGN dated on 2015-02-10: Earnings Scheduled For February 10, 2015

Financial news for REGN dated on 2015-01-26: US Stock Futures Signal Lower Start On Wall Street

Financial news for REGN dated on 2015-01-26: Regeneron, Sanofi Announce Praluent Biologics License Application Accepted for Priority Review by FDA

Financial news for REGN dated on 2015-01-23: Regeneron Pharmaceuticals' EYLEA

Injection Recommended For Approval By CHMP

Financial news for REGN dated on 2015-01-20: The 5 Biggest Biotech Stocks

Financial news for REGN dated on 2015-01-13: Notes From The Street: 'FLASHBACK....Oil Going To \$200/Barrel'

Financial news for REGN dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

Financial news for REGN dated on 2015-01-09: Regeneron, Sanofi Report Alirocumab Trials Met Primary Efficacy Endpoints

Financial news for REGN dated on 2015-01-06: J.P Morgan Just Chimed In With Ratings On Biotech Stocks

Financial news for REGN dated on 2015-01-06: UPDATE: Barclays Initiates Coverage On Regeneron

Financial news for REGN dated on 2015-01-06: CORRECTION: Barclays Initiates Coverage on Regeneron at Equal-weight, Announces \$450.00 PT

Financial news for REGN dated on 2015-01-05: Morgan Stanley Issues Wave Of Pharma & Medical Device Upgrades, Downgrades

Financial news for REGN dated on 2015-01-05: Morgan Stanley Upgrades Regeneron Pharmaceuticals to Overweight

Financial news for REGN dated on 2014-12-08: 3 Biotech ETFs Rally On Merger News

Financial news for REGN dated on 2014-12-02: A Look At 3 Overbought ETFs

Financial news for REGN dated on 2014-12-01: EYLEA Injection Accepted For Priority Review By FDA For Diabetic Retinopathy In Patients With Diabetic Macular Edema

Financial news for REGN dated on 2014-11-21: UPDATE: Bank Of America Reiterates On Regeneron Pharmaceuticals Following Several Positive Catalysts

Financial news for REGN dated on 2014-11-21: Bank of America Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to \$462.00

Financial news for REGN dated on 2014-11-20: UPDATE: Brean Capital Reiterates On Regeneron Pharmaceuticals On Increased Confidence

Financial news for REGN dated on 2014-11-20: Regeneron, Sanofi Announce Dupilumab Receives FDA Breakthrough Therapy Designation in Atopic Dermatitis

Financial news for REGN dated on 2014-11-20: Brean Capital Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to \$450.00

Financial news for REGN dated on 2014-11-19: Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

Financial news for REGN dated on 2014-11-18: US Stock Futures Mostly Flat Ahead Of Housing Data

Financial news for REGN dated on 2014-11-18: Regeneron Announces EYLEA Injection Approved for Treatment of DME in Japan

Financial news for REGN dated on 2014-11-11: Argus Research Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to \$450.00

Financial news for REGN dated on 2014-11-11: Regeneron, Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma

Financial news for REGN dated on 2014-11-04: Morning Market Losers

Financial news for REGN dated on 2014-11-04: From Regeneron Conf Call: Company Consulting With Government Agencies to See if Antibody Technologies Can Used to Combat Ebola Virus

Financial news for REGN dated on 2014-11-04: Benzinga's Top #PreMarket Losers

Financial news for REGN dated on 2014-11-04: Regeneron Pharmaceuticals, Inc. Reports Q3 EPS of \$2.52 vs \$2.57 Est; Revenue of \$726.0M vs \$733.04M Est

Financial news for REGN dated on 2014-11-04: Earnings Scheduled For November 4, 2014

Financial news for REGN dated on 2014-10-20: UPDATE: Regeneron, Sanofi Report Commencement of Phase 3 Study Of Dupilumab In Patients With AD

Financial news for REGN dated on 2014-10-20: Regeneron, Sanofi Report Commencement of Phase 3 Study of Dupilumab in Patients with AD

Financial news for REGN dated on 2014-10-17: TGIF As Markets Rally; S&P 500 Posts Longest Weekly Loss Streak Since 2011

Financial news for REGN dated on 2014-10-17: Benzinga's Volume Movers

Financial news for REGN dated on 2014-10-17: Amgen Reports Filing of Suit Against Sanofi, Regeneron for Patent Infringement, Seeking Injunction Related to PCSK9 Inhibitor

Financial news for REGN dated on 2014-10-17: UPDATE: Regeneron Shows Significant Improvement in BCVA, Primary Endpoint for Both Bevacizumab, Ranibizumab

Financial news for REGN dated on 2014-10-17: EYLEA Injection Demonstrates Significantly Greater Gains In Visual Acuity than Both Bevacizumab And Ranibizumab In NIH-Sponsored Diabetic Macular Edema Study

Financial news for REGN dated on 2014-10-16: Regeneron Genetics Center Fully Operational, Announces New Collaborations And Key Appointments

Financial news for REGN dated on 2014-10-06: Regeneron's EYLEA (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO)

Financial news for REGN dated on 2014-10-02: Guggenheim Securities Initiates Coverage on Regeneron Pharmaceuticals, Inc. at Buy , Announces \$432.00 PT

Financial news for REGN dated on 2014-09-22: Regeneron Announces EYLEA Injection Approved for Treatment of Patients with Myopic Choroidal Neovascularization in Japan

Financial news for REGN dated on 2014-09-18: UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Inc Following DME Doc Event

Financial news for REGN dated on 2014-09-16: Deutsche Bank Is Bullish On Gilead Sciences, Inc. And Other Biotech Stocks

Financial news for REGN dated on 2014-09-16: Regeneron Reports EYLEA Injection Received FDA Breakthrough Therapy Designation, SBLA Expected to Be Submitted by Year End

Financial news for REGN dated on 2014-09-02: Brean Capital Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to \$390.00

Financial news for REGN dated on 2014-09-02: UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Ahead Of Conference Call

Financial news for REGN dated on 2014-08-31: Regeneron, Sanofi Announce Four Pivotal Alirocumab Trials All Met Primary Efficacy Eendpoint

Financial news for REGN dated on 2014-08-11: Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments

Financial news for REGN dated on 2014-08-05: Ukraine Tension Prominent As Dow Suffers Triple Digit Loss; S&P 500 & NASDAQ Also Lower

Financial news for REGN dated on 2014-08-05: Deutsche Bank Raises Regeneron's Price Target To \$425

Financial news for REGN dated on 2014-08-05: Deutsche Bank Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to \$425.00

Financial news for REGN dated on 2014-08-05: UPDATE: Regeneron Posts Upbeat Q2 Results

Financial news for REGN dated on 2014-08-05: Regeneron Pharmaceuticals, Inc. Reports Q2 EPS of \$2.47 vs \$2.28 Est; Revenue of \$666.0M vs \$647.61M Est

Financial news for REGN dated on 2014-08-05: Earnings Scheduled For August 5, 2014

Financial news for REGN dated on 2014-07-31: Amended 13D Filing from Sanofi on Regeneron Shows Co. Has Confirmed 22.5% Stake in REGN as of Jul. 30th, Planning to Buy 30% Stake This Year and Next

Financial news for REGN dated on 2014-07-30: Regeneron And Sanofi To Use Priority

Review Voucher For FDA Submission

Financial news for REGN dated on 2014-07-30: Regenero and Sanofi Announces Positive Top Line Results For Alirocumab Phase 3 Trials

Financial news for REGN dated on 2014-07-30: Sanofi And Regeneron Report Positive Top-Line Results From Nine Phase 3 Trials Of Alirocumab In People With Hypercholesterolemia

Financial news for REGN dated on 2014-07-29: UPDATE: Regeneron Shares Now at \$316 After-Hours Following FDA Approval of Eylea Injection for DME

Financial news for REGN dated on 2014-07-29: Regeneron Resumes Trading

Financial news for REGN dated on 2014-07-29: PREVIEW: Regeneron to Resume Trading at 7:00 PM ET

Financial news for REGN dated on 2014-07-29: Regeneron Announces EYLEA Injection Has Received FDA Approval for Treatment of DME

Financial news for REGN dated on 2014-07-29: Shares of Regeneron Pharma Halted News Pending

Financial news for REGN dated on 2014-07-21: Argus Research Initiates Coverage on Regeneron Pharmaceuticals, Inc. at Buy

Financial news for REGN dated on 2014-07-18: Regeneron Announces Two-Year Results from Phase 3 VIVID-DME Trial Of EYLEA Injection for Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision

Financial news for REGN dated on 2014-07-10: UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Following Good Results Of Drug Study

Financial news for REGN dated on 2014-07-10: Benzinga's Top #PreMarket Gainers

Financial news for REGN dated on 2014-07-09: UPDATE: Regeneron, Sanofi Offer Positive Results from Phase 2b Study of Dupilum, All Doses Met Primary Endpoint

Financial news for REGN dated on 2014-07-09: Regeneron, Sanofi Offer Positive Results from Phase 2b Study of Dupilum, All Doses Met Primary Endpoint

Financial news for REGN dated on 2014-07-08: Regeneron Pharmaceuticals Shareholder Sanofi Buys 356,700 Shares @\$312.37/Share -Form 4

Financial news for REGN dated on 2014-07-03: Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

Financial news for REGN dated on 2014-07-01: Amended 13D from Sanofi on Regeneron Pharma Shows Firm to Raise Ownership Stake from 20.44% as of May 19th to 22.5%

Financial news for REGN dated on 2014-06-27: US Stock Futures Drop Ahead Of Consumer Sentiment Report

Financial news for REGN dated on 2014-06-27: EYLEA Injection Recommended For Approval Regarding Treatment Of Visual Impairment Due To Diabetic Macular Edema In The European Union

Financial news for REGN dated on 2014-06-20: Regeneron Shares Fall Following BMO's Note Of Roche Preference

Financial news for REGN dated on 2014-06-20: Watch Shares of Regeneron Right Now as CNBC Just Highlighted Earlier Negative Note from BMO, Suggested Eylea Patients Switching to Avastin

Financial news for REGN dated on 2014-06-19: Judge Denies Merus BV's Motion to Dismiss Regeneron's Patent Infringement Suit -Reuters

Financial news for REGN dated on 2014-06-12: US Stock Futures Edge Higher Ahead Of Jobless Claims, Retail Sales Data

Financial news for REGN dated on 2014-06-12: Sanofi and Regeneron Announce Sarilumab Met All Three Co-Primary Endpoints

Financial news for REGN dated on 2014-06-11: US Stock Futures Tumble; World Bank Lowers Global Growth Outlook

Financial news for REGN dated on 2014-06-11: EYLEA Injection Submitted for EU Marketing Authorization for Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion

Financial news for REGN dated on 2014-05-11: Surges In Biotech Short Interest (INCY, PCYC, REGN)

Financial news for REGN dated on 2014-05-08: Regeneron Pharmaceuticals Reports Q1 Adjusted EPS of \$2.26 vs \$2.20 Est; Revenue of \$625.70M vs \$609.04M Est

Financial news for REGN dated on 2014-05-05: Regeneron, Avalanche Announces Development Deal for Gene Therapy for Ophthalmology, Avalanche Will Get Upfront Payment, Contingent Payments of Up to \$640M

Financial news for REGN dated on 2014-04-24: RBC Optimistic on Regeneron Following Lower Sales by Novartis' Lucentis

Financial news for REGN dated on 2014-04-16: Market Wrap For April 16: Markets Hold On To Gains On Positive Yellen Comments And Economic Data

Financial news for REGN dated on 2014-04-16: UPDATE: Canaccord Genuity Initiates Coverage on Regeneron Pharmaceuticals on Expected Continued Pipeline Success

Financial news for REGN dated on 2014-04-16: Benzinga's Top Initiations

Financial news for REGN dated on 2014-04-16: Canaccord Genuity Initiates Coverage on Regeneron Pharmaceuticals, Inc. at Buy, Announces \$350.00 PT

Financial news for REGN dated on 2014-04-11: Top 40 Upcoming Earnings Releases

Financial news for REGN dated on 2014-04-08: Biotechs Struggling To Find A Bottom

Financial news for REGN dated on 2014-04-04: Regeneron Names Robert Ingram to Board

Financial news for REGN dated on 2014-04-03: Regeneron Announces Initiative for STEM Education in Hudson Valley

Financial news for REGN dated on 2014-04-01: Sanofi, Regeneron Announce Primary Endpoint in Phase 2 Japanese Study of Alirocumab Met, PCSK9 Significantly Reduced LDL-C

Financial news for REGN dated on 2014-03-31: Regeneron Shares Flirting with Session Highs as Roth Boosts Price Target from \$362 to \$382

Financial news for REGN dated on 2014-03-27: Market Wrap For March 27: Markets Lower Following Mixed Economic Data

Financial news for REGN dated on 2014-03-27: Morgan Stanley's Top Biotech Pick is Biogen

Financial news for REGN dated on 2014-03-27: US Stock Futures Rise; GDP, Jobless Claims Data In Focus

Financial news for REGN dated on 2014-03-27: Morgan Stanley Initiates Coverage on Regeneron Pharmaceuticals, Inc. at Equal-weight, Announces \$320.00 PT

Financial news for REGN dated on 2014-03-27: Sanofi, Regeneron to Present Alirocumab Clinical Data at ACCs 63rd Annual Scientific Session

Financial news for REGN dated on 2014-03-17: UPDATE: Citigroup Upgrades Regeneron Pharmaceuticals

Financial news for REGN dated on 2014-03-17: Citigroup Upgrades Regeneron Pharmaceuticals, Inc. to Buy

Financial news for REGN dated on 2014-03-07: UPDATE: Sanofi and Regeneron Unaware of Neurocognitive Adverse Event Signal Related to Alirocumab, Sanofi Says

Financial news for REGN dated on 2014-03-07: Regeneron 10-K Filing from February 13 Mentions Adverse Events Related to PCSK9

Financial news for REGN dated on 2014-03-07: Adam Feuerstein Tweet: '\$REGN 10-K filed Feb. 13 contains exact same language used by \$SNY in 20-F. No one seemed to notice.'

Financial news for REGN dated on 2014-03-07: Regeneron Shares Resume, Now Down ~8.5%

Financial news for REGN dated on 2014-03-07: UPDATE: Sanofi's 20-F Filing Was Out Just After 11AM EST

Financial news for REGN dated on 2014-03-07: UPDATE: Bloomberg Reporting on Adverse Events Related to PCSK9, Says News Was Out in Sanofi's Form 20-F Filing Earlier

Financial news for REGN dated on 2014-03-07: Downside in Regeneron Could Related to FDA Advisory on Adverse Events Related to PCSK9

Financial news for REGN dated on 2014-03-07: Regeneron Pharma Shares Halted on Circuit Breaker, Now Down 10%

Financial news for REGN dated on 2014-03-03: Bayer, Regeneron Announce Regulatory Submission of EYLEA Injection for Treatment of DME in Japan

Financial news for REGN dated on 2014-02-24: UPDATE: Cramer's Momentum Monster Stocks: Priceline, Regeneron, Solar City, Stratasys, Tesla, Twitter, Under Armour, Workday, Yelp

Financial news for REGN dated on 2014-02-24: UPDATE: Regeneron Announces FDA Acceptance of EYLEA(r) (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion

Financial news for REGN dated on 2014-02-24: Regeneron Reports FDA Acceptance of EYLEA

Financial news for REGN dated on 2014-02-13: Oppenheimer Downgrades Regeneron Pharmaceuticals, Inc. to Market Perform, Raises PT to \$325.00

Financial news for REGN dated on 2014-02-12: Bank of America Reinstates Buy on Regeneron Pharmaceuticals, Inc., Announces \$387.00 PT

Financial news for REGN dated on 2014-02-11: Market Wrap For February 11: Yellen Re-assures Markets & Wakes Up The Sleeping Bulls

Financial news for REGN dated on 2014-02-11: Regeneron Pharmaceuticals Continue Higher Following a Mid-Day Report from Deutsche Bank

Financial news for REGN dated on 2014-02-11: UPDATE: Deutsche Bank on Regeneron Said Key Takeaway from Q4 Call Was 'Tax Benefit from Ireland Manufacturing, Moving IPs for Antibodies Which Could Lower Tax Rate Starting 2017'

Financial news for REGN dated on 2014-02-11: Deutsche Bank Lifts Target on Regeneron to New Street High of \$410

Financial news for REGN dated on 2014-02-11: Top Trending Tickers On StockTwits For February 11

Financial news for REGN dated on 2014-02-11: Regeneron Said Expecting FY14 Eylea US Net Sales \$1.7-1.8B, Capex \$350-425M

Financial news for REGN dated on 2014-02-11: Regeneron Pharmaceuticals Reports Q4 Adjusted EPS of \$2.24 vs \$0.98 Est; Revenue of \$610.0M vs \$580.47M Est

Financial news for REGN dated on 2014-02-11: Earnings Scheduled For February 11, 2014

Financial news for REGN dated on 2014-02-10: UPDATE: Regeneron Reports Two-Year Results from Phase 3 VISTA Trail of Eylea, Says Showed Sustained Improvement in Vision

Financial news for REGN dated on 2014-02-10: Regeneron Reports Two-Year Results from Phase 3 VISTA Trail of Eylea, Says Showed Sustained Improvement in Vision

Financial news for REGN dated on 2014-01-16: UPDATE: SEC Filing from Regeneron Shows Bayer Prohibited from Purchase 20+% Stake

Financial news for REGN dated on 2014-01-16: Form 8-K from Regeneron Pharma Shows Co. Says Bayer Agreed to a Standstill

Financial news for REGN dated on 2014-01-15: Benzinga's Top Downgrades

Financial news for REGN dated on 2014-01-15: BMO Capital Downgrades Regeneron Pharmaceuticals, Inc. to Market Perform, Maintains \$331.00 PT

Financial news for REGN dated on 2014-01-14: Regeneron Pharmaceuticals CEO Schleifer: 'We have a Great Relationship with Sanofi'

Financial news for REGN dated on 2014-01-14: Regeneron Pharmaceuticals CEO Schleifer: 'The Data from the Phase 3 Trial of Our Cholesterol Drug has been Positive So Far'

Financial news for REGN dated on 2014-01-14: Regeneron Pharmaceuticals CEO Schleifer: 'There has been an Epidemic of Allergic Diseases'

Financial news for REGN dated on 2014-01-14: Regeneron Pharmaceuticals CEO Schleifer:

'We Think Eylea has Opportunity to Grow'

Financial news for REGN dated on 2014-01-14: Jim Cramer Interviews CEO Dr. Leonard S. Schleifer of Regeneron Pharmaceuticals on Mad Money

Financial news for REGN dated on 2014-01-14: From Regeneron Presentation at JP Morgan Healthcare Conference: Reports Prelim. US Eylea Sales ~\$400M, Sees FY14 Capital Spending \$350-425M

Financial news for REGN dated on 2014-01-13: UPDATE: Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration; Bayer Retains Exclusive Commercialization Rights Outside US; Regeneron Retains Full US Rights

Financial news for REGN dated on 2014-01-13: Regeneron, Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration

Financial news for REGN dated on 2014-01-13: Regeneron, Bayer Will Develop New Treatment Option for WetAMD, Regeneron Will Get Upfront Payment of \$25.5M

Financial news for REGN dated on 2013-12-18: Regeneron Announces FDA Acceptance of Eylea SBLA to Treat DME, Sets PDUFA Date as Aug. 18th, 2014

Financial news for REGN dated on 2013-11-27: UPDATE: Piper Jaffray Initiates Coverage on Regeneron Pharmaceuticals as 2014 Biotech Sector Outlook Remains Strong

Financial news for REGN dated on 2013-11-22: US Stock Futures Flat After Record Close

Financial news for REGN dated on 2013-11-22: EYLEA Injection Approved for Treatment of Macular Edema Following CRVO In Japan

Financial news for REGN dated on 2013-11-22: Sanofi, Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial

Financial news for REGN dated on 2013-11-15: Downside Protection For Regeneron Pharmaceuticals

Financial news for REGN dated on 2013-11-15: Downside Protection For Regeneron Pharmaceuticals

Financial news for REGN dated on 2013-11-14: FDA Says Outcomes Trials Are Not Needed for PCSK9 Approval

Financial news for REGN dated on 2013-11-12: Gilead Sciences Leads In Rising Short Interest Among Biotechs

Financial news for REGN dated on 2013-11-05: Regeneron CEO Schleifer: 'We are Getting Close to a Treatment for Allergic Diseases'

Financial news for REGN dated on 2013-11-05: Regeneron CEO Schleifer: 'There are Still Opportunities for Us to Grow Eylea in US'

Financial news for REGN dated on 2013-11-05: Regeneron CEO Schleifer: 'We have a Very Strong Partnership with Sanofi'

Financial news for REGN dated on 2013-11-05: Jim Cramer Interviews CEO Leonard S. Schleifer of Regeneron Pharmaceuticals on Mad Money

Financial news for REGN dated on 2013-11-05: Market Wrap: Stocks End Flat, but Tesla Shares Sag After Hours

Financial news for REGN dated on 2013-11-05: Deutsche Bank Maintains Overweight on Regeneron Pharmaceuticals, Inc., Raises PT to \$376.00

Financial news for REGN dated on 2013-11-05: Deutsche Bank Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to \$375.00

Financial news for REGN dated on 2013-11-05: Regeneron Pharma Files Automatic Mixed Securities Shelf

Financial news for REGN dated on 2013-11-05: Regeneron Pharmaceuticals Reports Q3 Adjusted EPS of \$2.40 Which May Not Compare \$0.90 Est; Revenue of \$597.0M Which May Not Compare \$502.78M Est

Financial news for REGN dated on 2013-11-03: Earnings Expectations For The Week Of November 4: Disney, Tesla, Groupon And More

Financial news for REGN dated on 2013-11-01: Benzinga Weekly Preview: Central Banks Back In The Spotlight

Financial news for REGN dated on 2013-10-25: Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)

Financial news for REGN dated on 2013-10-21: Regeneron Says Phase 3 Data on Eylea Shows 53% Gained At Least 15 Letters in Vision

Financial news for REGN dated on 2013-10-18: UPDATE: Leerink Swann Downgrades Sanofi Based on Low Visibility

Financial news for REGN dated on 2013-10-16: Sanofi Regeneron Report Phase 3 ODYSSEY MONO trial with Alirocumab Met Primary Efficacy Endpoint

Financial news for REGN dated on 2013-10-11: Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

Financial news for REGN dated on 2013-10-01: Bank of America Raises Target on Regeneron Pharma from \$310 to \$345

Financial news for REGN dated on 2013-09-30: UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals Following Complete Phase 3 Eye Drug Data

Financial news for REGN dated on 2013-09-30: UPDATE: Oppenheimer Raises PT on Regeneron Pharmaceuticals Following Results of VIVID & VISTA Studies

Financial news for REGN dated on 2013-09-30: UPDATE: Piper Jaffray Raises PT on Regeneron Pharmaceuticals Following Presentation of EYLEA DME Data

Financial news for REGN dated on 2013-09-30: Goldman Sachs Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to \$355.00

Financial news for REGN dated on 2013-09-30: Cramer on CNBC Says 'Watch for Bounce' in Regeneron Pharma Shares

Financial news for REGN dated on 2013-09-30: Oppenheimer Maintains Outperform on Regeneron Pharmaceuticals, Inc., Raises PT to \$310.00

Financial news for REGN dated on 2013-09-30: Piper Jaffray Maintains Overweight on Regeneron Pharmaceuticals, Inc., Raises PT to \$360.00

Financial news for REGN dated on 2013-09-25: BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

Financial news for REGN dated on 2013-09-18: Traders in Regeneron Pharma Responding to Boosted Price Target from \$298 to \$329 at Goldman Sachs, Firm Maintains Buy; Stock Up 3% to \$305.60

Financial news for REGN dated on 2013-09-14: Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)

Financial news for REGN dated on 2013-09-13: Lazard Capital Markets Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to \$325.00

Financial news for REGN dated on 2013-09-10: Regeneron Names Robert Landry as Senior VP, Finance, CFO

Financial news for REGN dated on 2013-08-27: Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)

Financial news for REGN dated on 2013-08-21: Oppenheimer Initiates Coverage on Regeneron Pharmaceuticals, Inc. at Outperform, Announces \$300.00 PT

Financial news for REGN dated on 2013-08-21: Oppenheimer Initiates Coverage on Regeneron Pharmaceuticals, Inc. at Outperform, Announces \$300.00 PT

Financial news for REGN dated on 2013-08-06: Piper Jaffray Raises Target on Regeneron Pharma from \$274 to \$336, Maintains Overweight

Financial news for REGN dated on 2013-08-06: Benzinga's Top Pre-Market Losers

Financial news for REGN dated on 2013-08-06: Regeneron, Bayer Report Positive Results from Phase 3 Trials of EYLEA Injection for Treatment of Diabetic Macular Edema

Financial news for REGN dated on 2013-07-26: Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

Financial news for REGN dated on 2013-07-26: Regeneron Drug Receives Positive Recommendation From European Authorities

Financial news for REGN dated on 2013-07-14: Biotech to Watch: Alnylam

Pharmaceuticals Soars on Drug Data (ALNY)

Financial news for REGN dated on 2013-07-12: Lazard Capital Markets Upgrades Regeneron Pharmaceuticals, Inc. to Buy, Announces \$298.00 PT

Financial news for REGN dated on 2013-07-11: Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)

Financial news for REGN dated on 2013-07-10: What to Expect From Tesla Shares After Joining QQQ (TSLA)

Financial news for REGN dated on 2013-07-03: RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Financial news for REGN dated on 2013-07-02: BMO Says Biotech Sector Could See Upside from M&A, Offers Multiple Attractive Targets

Financial news for REGN dated on 2013-07-01: UPDATE: Piper Jaffray Upgrades Regeneron Pharmaceuticals to Overweight Following EYLEA Launch

Financial news for REGN dated on 2013-07-01: Benzinga's Top Upgrades

Financial news for REGN dated on 2013-07-01: Piper Jaffray Upgrades Regeneron Pharmaceuticals, Inc. to Overweight, Maintains \$274.00 PT

Financial news for REGN dated on 2013-06-28: SLIDESHOW: Top 10 Performing S&P 500 Stocks of the Second Quarter

Financial news for REGN dated on 2013-06-26: Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)

Financial news for REGN dated on 2013-06-18: Jefferies Says Analysis on Elan Supports \$19/Share Takeover Bid, Lifts Price Target to \$19

Financial news for REGN dated on 2013-06-12: Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)

Financial news for REGN dated on 2013-06-06: Market Wrap for Thursday, June 6: Stocks Reverse Mid-Day; Rally to Close at Session Highs

Financial news for REGN dated on 2013-06-06: Regeneron and Bayer Announce Positive Phase 3 Results for EYLEA Injection

Financial news for REGN dated on 2013-05-29: Short Interest in Vertex Rises, in Biogen Idec Falls

Financial news for REGN dated on 2013-05-21: Sanofi, Regeneron Says Phase 2a Trial of Dupilumab Demonstrated 87% Cut in Asthma Risk

Financial news for REGN dated on 2013-05-20: Form 8-K Showing Regeneron, Genentech Announced Deals on Worldwide Sales of Eylea

Financial news for REGN dated on 2013-05-15: Sanofi, Regeneron Announce Patient Enrollment in Two Phase 3 Sarilumab Trials for Rheumatoid Arthritis

Financial news for REGN dated on 2013-05-11: Short Interest in Vertex Rises, in Celgene Falls

Financial news for REGN dated on 2013-05-06: UPDATE: Jefferies Raises PT on Regeneron Pharmaceuticals Following Top-Line Q1 Beat

Financial news for REGN dated on 2013-05-03: Market Wrap for Friday, May 3: Stocks Jump on Strong Jobs Data

Financial news for REGN dated on 2013-05-03: Brean Capital Upgrades Regeneron Pharmaceuticals, Inc. to Buy, Announces \$315.00 PT

Financial news for REGN dated on 2013-05-03: A Peek Into The Market Before The Trading Starts

Financial news for REGN dated on 2013-05-03: Regeneron Acquires Rights to Two Families of Novel Antibodies

Financial news for REGN dated on 2013-05-03: Regeneron Pharmaceuticals Reports Q1 EPS Ex-Items of \$1.78 vs \$0.95 Est; Revenue of \$439.66M vs \$424.26M Est

Financial news for REGN dated on 2013-05-01: Regeneron Pharmaceuticals: The Stock That Only Goes Up?

Financial news for REGN dated on 2013-05-01: Market Wrap for Wednesday, May 1: Stocks Fall as Employment Data Weakens in April

Financial news for REGN dated on 2013-05-01: Allergan Says DARPin Data Do Not Support Phase 3 Trials, Will Delay Study -Bloomberg

Financial news for REGN dated on 2013-05-01: Regeneron Circuit Breaker on Volatility

Financial news for REGN dated on 2013-05-01: UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals Following Cardiologist/Lipidologist Survey

Financial news for REGN dated on 2013-05-01: Goldman Sachs Maintains Conviction Buy on Regeneron Pharmaceuticals, Inc., Raises PT to \$240.00

Financial news for REGN dated on 2013-04-30: Stocks to Watch for April 30, 2013

Financial news for REGN dated on 2013-04-26: Short Sellers Move into Celgene, Regeneron

Financial news for REGN dated on 2013-04-24: S&P Says Regeneron to Join S&P 500

Financial news for REGN dated on 2013-04-12: Bank of America Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PO to \$220.00

Financial news for REGN dated on 2013-04-10: Short Sellers Move Out of Amgen, Celgene, Pharmacyclics

Financial news for REGN dated on 2013-04-09: Stocks Hitting 52-Week Highs

Financial news for REGN dated on 2013-04-09: UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals on Strong Eylea Launch

Financial news for REGN dated on 2013-04-09: Goldman Sachs Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to \$215.00

Financial news for REGN dated on 2013-04-04: Regeneron Pharma to Expand Corporate HQ, Labs in Westchester County

Financial news for REGN dated on 2013-03-28: JMP Securities Initiates Coverage on Regeneron Pharmaceuticals, Inc. at Market Perform

Financial news for REGN dated on 2013-03-28: Short Sellers Dump Amgen, Focus on Celgene, Gilead Sciences

Financial news for REGN dated on 2013-03-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, PCYC)

Financial news for REGN dated on 2013-03-04: Regeneron Pharma Announces Possible Added Royalty Stream Related to EU Approval for Ilaris

Financial news for REGN dated on 2013-03-02: Sanofi, Regeneron Report Positive Phase 1b Data for Dupilumab in Atopic Dermatitis

Financial news for REGN dated on 2013-02-28: Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)

Financial news for REGN dated on 2013-02-28: Barclays Initiated Coverage on Regeneron Pharmaceuticals, Inc. at Overweight, Announced \$194.00 PT

Financial news for REGN dated on 2013-02-19: A Peek Into The Market Before The Trading Starts

Financial news for REGN dated on 2013-02-19: Regeneron, Bayer Initiate Phase 3 Trial of EYLEA Injection for Treatment of Diabetic Macular Edema in Asia and Russia

Financial news for REGN dated on 2013-02-14: Earnings Scheduled For February 14, 2013

Financial news for REGN dated on 2013-02-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

Financial news for REGN dated on 2013-02-11: JP Morgan Cautious on Sanofi Buying Regeneron

Financial news for REGN dated on 2013-02-11: Regeneron Pharma Shares Resume Trading Up ~8%

Financial news for REGN dated on 2013-02-11: Sanofi Says No Plan to Take Controlling Stake in Regeneron, Says Could Increase Stake Over Time - Bloomberg

Financial news for REGN dated on 2013-02-11: Regeneron Pharma Shares to Resume Trade at 10:05AM EST

Financial news for REGN dated on 2013-02-11: UPDATE: Regeneron Pharm Announces Receipt of HSR Notice Sanofi to Buy Stock in Open Market

Financial news for REGN dated on 2013-02-11: Regeneron Announces Receipt of HSR Notice Sanofi Intends to buy Stock in Open Market

Financial news for REGN dated on 2013-02-11: Regeneron Halted News Pending

Financial news for REGN dated on 2013-02-04: Jefferies Reiterates Buy Rating, \$34 PT on Partnership with Alnylam Pharmaceuticals

Financial news for REGN dated on 2013-01-26: Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

Financial news for REGN dated on 2013-01-18: EMA Says Novartis, Regeneron Win Backing for Ilaris

Financial news for REGN dated on 2013-01-17: Brean Capital Downgrades Regeneron Pharmaceuticals, Inc. to Hold, Removes \$180.00 PT

Financial news for REGN dated on 2013-01-15: UPDATE: Jefferies Downgrades Regeneron Pharmaceuticals to Hold on Limited Eylea Upside

Financial news for REGN dated on 2013-01-15: Jefferies Downgrades Regeneron Pharmaceuticals, Inc. to Hold, Maintains \$179.00 PT

Financial news for REGN dated on 2013-01-08: Regeneron CEO Schleifer: 'It's Hard to Figure Out What People Expect, But there was a Problem with Compounding Pharmacies'

Financial news for REGN dated on 2013-01-08: Regeneron CEO Schleifer: 'If We Put the Cash on Research, We'll Be in Good Shape'

Financial news for REGN dated on 2013-01-08: Regeneron CEO Schleifer: 'Our Franchise is Going Well Despite the Fact We Weren't Able to Deliver on Everything Expected'

Financial news for REGN dated on 2013-01-08: Jim Cramer Interviews CEO Dr. Leonard S. Schleifer of Regeneron Pharmaceuticals on Mad Money

Financial news for REGN dated on 2013-01-08: Regeneron Pharmaceuticals, Inc. Reports Q4 Revenue of \$276.0M vs \$264.20M Est; Sees 2013 Eylea Sales Growth ~50%

Financial news for REGN dated on 2013-01-05: Benzinga's M&A Chatter for Friday January 4, 2013

Financial news for REGN dated on 2013-01-04: Regeneron Recommends Rejection of Mini-Tender Offer by TRC Capital

Financial news for REGN dated on 2012-12-28: Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

Financial news for REGN dated on 2012-12-20: These Three Prominent Stocks Have Doubled in 2012

Financial news for REGN dated on 2012-12-12: Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

Financial news for REGN dated on 2012-12-06: Regeneron's EYLEA Submitted for EU Marketing Authorization for Treatment of Macular Edema

Financial news for REGN dated on 2012-11-27: Regeneron's EYLEA Injection Approved for Treatment of Wet Age-Related Macular Degeneration by EC

Financial news for REGN dated on 2012-11-19: Watchlist For Next Week

Financial news for REGN dated on 2012-11-16: From Earlier: CHMP Recommends Granting of Marketing Authorization for ZALTRAP

Financial news for REGN dated on 2012-11-13: UPDATE: Credit Suisse Initiates Regeneron Pharmaceutical at Outperform

Financial news for REGN dated on 2012-11-12: Credit Suisse Initiates Coverage on Regeneron Pharmaceuticals at Outperform, Announces PT of \$187

Financial news for REGN dated on 2012-11-12: Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

Financial news for REGN dated on 2012-11-05: Sanofi, Regeneron Begin Enrollment in CV Outcomes Trial with PCSK9 Antibody for Hypercholesterolemia

Financial news for REGN dated on 2012-10-25: Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

Financial news for REGN dated on 2012-10-25: Stocks To Watch For October 25, 2012

Financial news for REGN dated on 2012-10-25: Deutsche Bank Maintains Regeneron Pharmaceuticals at Buy, Raises PT from \$165 to \$190

Financial news for REGN dated on 2012-10-24: Rating Breakdown: Best & Worst ETFs & Mutual Funds by Sector

Financial news for REGN dated on 2012-10-24: Goldman Sachs Maintains Regeneron Pharmaceuticals at Buy, Raises PT from \$170 to \$175

Financial news for REGN dated on 2012-10-24: Deutsche Bank Maintains Regeneron Pharmaceuticals at Buy, Raises PT from \$165 to \$190

Financial news for REGN dated on 2012-10-24: Citi Maintains Regeneron Pharmaceuticals at Neutral, Raises PT from \$151 to \$182

Financial news for REGN dated on 2012-10-24: Jefferies & Company Maintains Regeneron Pharmaceuticals at Buy, Raises PT from \$161 to \$179

Financial news for REGN dated on 2012-10-24: Citi Raises PT on Regeneron Pharmaceuticals from \$151 to \$182

Financial news for REGN dated on 2012-10-24: From Earlier: Regeneron Pharmaceuticals Reports Q3 EPS \$1.89 vs \$0.95 Est; Revenues \$427.7M vs \$349.17M Est

Financial news for REGN dated on 2012-10-22: Leerink Swann Raises PT on Regeneron Pharmaceuticals from \$150 to \$182

Financial news for REGN dated on 2012-10-18: Regeneron Announces Publication of EYLEA (afibercept) Injection Phase 3

Financial news for REGN dated on 2012-10-15: Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)

Financial news for REGN dated on 2012-10-10: Regeneron Pharmaceuticals Spikes Higher

Financial news for REGN dated on 2012-09-28: Regeneron's EYLEA Injection Approved for Treatment of Wet Age-Related Macular Degeneration in Japan

Financial news for REGN dated on 2012-09-26: Short Interest in Biotech Firms Resumes (BIIB, GILD, ILMN, REGN)

Financial news for REGN dated on 2012-09-24: UPDATE: Goldman Sachs Raises PT to \$170 on Regeneron Pharmaceuticals on Eylea EU Approval

Financial news for REGN dated on 2012-09-24: UPDATE: Bank of America Raises PO to \$172 on Regeneron Pharmaceuticals on EU Approval

Financial news for REGN dated on 2012-09-24: Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from \$168 to \$172

Financial news for REGN dated on 2012-09-24: Piper Jaffray Maintains Regeneron Pharmaceuticals at Neutral, Raises PT from \$128 to \$140

Financial news for REGN dated on 2012-09-21: Regeneron Announces FDA Approval of EYLEA

Financial news for REGN dated on 2012-09-21: Regeneron Pharma Says Eylea Injection Recommend for Approval by CHMP

Financial news for REGN dated on 2012-09-17: Goldman Sachs Maintains Regeneron Pharmaceuticals at Buy, Raises PT from \$160 to \$168

Financial news for REGN dated on 2012-08-28: Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from \$164 to \$168

Financial news for REGN dated on 2012-08-28: Regeneron Spikes to 52-Week High, \$147.00

Financial news for REGN dated on 2012-08-28: Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from \$164 to \$168

Financial news for REGN dated on 2012-08-23: Benzinga's M&A Chatter for Thursday August 23, 2012

Financial news for REGN dated on 2012-08-23: Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Financial news for REGN dated on 2012-08-23: Regeneron Pharmaceuticals Hits 52-Week High on Takeover Rumors

Financial news for REGN dated on 2012-08-23: Hearing Unconfirmed Takeover Chatter in Regeneron

Financial news for REGN dated on 2012-08-23: Regeneron Pharmaceuticals Spikes Higher

Financial news for REGN dated on 2012-08-21: Bank of America Adds Questcor to US 1 List, Removes Regeneron Pharma

Financial news for REGN dated on 2012-08-13: Regeneron CEO Schleifer: 'Eylea Only Treatments for Macular Degeneration Approved by FDA to be Used Every Other Month'

Financial news for REGN dated on 2012-08-13: Regeneron CEO Schleifer: 'Eylea Could be One of the Best Launches in the History of the Biopharmaceutical Industry'

Financial news for REGN dated on 2012-08-13: Regeneron CEO Schleifer: 'Eylea Only Approved in US; Expect to Launch Our First Countries Outside of US in Q4'

Financial news for REGN dated on 2012-08-13: Jim Cramer Interviews CEO Leonard S. Schleifer of Regeneron Pharmaceuticals on Mad Money

Financial news for REGN dated on 2012-08-13: PREVIEW: Jim Cramer to Interview CEO's of Regeneron, Charles River on Mad Money

Financial news for REGN dated on 2012-08-13: Short Sellers Shy Away from Biotech Firms

Financial news for REGN dated on 2012-08-03: Regeneron, Sanofi Win FDA Approval for Colon Cancer Drug Zaltrap

Financial news for REGN dated on 2012-07-25: Social Media Outlook for Wednesday July 25 (RVBD, REGN, IGT, NFLX)

Financial news for REGN dated on 2012-07-25: Piper Jaffray Maintains Regeneron Pharmaceuticals at Neutral, Raises PT from \$113 to \$128

Financial news for REGN dated on 2012-07-25: Regeneron Plunges From Open After Earnings; Stock Still Higher

Financial news for REGN dated on 2012-07-25: BMO Capital Markets Upgrades Regeneron Pharmaceuticals from Market Perform to Outperform

Financial news for REGN dated on 2012-07-25: Regeneron Pharmaceuticals Reports Q2 EPS \$0.90 vs \$0.27 Est; Revenues \$304.4M vs \$257.05M Est

Financial news for REGN dated on 2012-07-20: Financial Breakfast: Morning News Summary for July 20, 2012

Financial news for REGN dated on 2012-07-20: Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody

Financial news for REGN dated on 2012-07-18: Biotechs With Upcoming PDUFA Dates

Financial news for REGN dated on 2012-07-05: S&P: Not All Mid-Cap ETFs Created Equal (MDY, VO)

Financial news for REGN dated on 2012-07-02: Trading the Trend: Regeneron, Alexion, TripAdvisor, Expedia All Pushing Higher

Financial news for REGN dated on 2012-06-28: Ultimate Stock Watch List for The Supreme Court's Health Care Ruling

Financial news for REGN dated on 2012-06-13: Regeneron Plunging; May be Related to Drug Data From Ophthotech

Financial news for REGN dated on 2012-06-13: Jefferies Maintains Buy on Regeneron After Positive Data

Financial news for REGN dated on 2012-06-13: JP Morgan Comments on Wet AMD Data for Regeneron

Financial news for REGN dated on 2012-05-29: UPDATE: Bank of America Raises Regeneron Pharmaceuticals' PO

Financial news for REGN dated on 2012-05-29: Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from \$154 to \$158

Financial news for REGN dated on 2012-05-09: Goldman Sachs Maintains Regeneron Pharmaceuticals at Buy, Lowers PT from \$157 to \$155

Financial news for REGN dated on 2012-05-09: Regeneron Reports That It Will Attend JP Morgan Biotech Conference

Financial news for REGN dated on 2012-05-09: UPDATE: Jefferies Lowers Regeneron Pharmaceuticals' PT

Financial news for REGN dated on 2012-05-09: Jefferies & Company Maintains Regeneron Pharmaceuticals at Buy, Lowers PT from \$163 to \$161

Financial news for REGN dated on 2012-05-08: FDA Panel Votes 11 to 0 to Reject Regeneron's Arcalyst for Gout Flares

Financial news for REGN dated on 2012-05-08: FDA Panel Votes 3 Yes 8 No on Question of Regeneron Arcalyst Safety

Financial news for REGN dated on 2012-05-08: Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from \$150 to \$154

Financial news for REGN dated on 2012-04-27: Jefferies & Company Maintains Regeneron Pharmaceuticals at Buy, Raises PT from \$127 to \$163

Financial news for REGN dated on 2012-04-26: Piper Jaffray Maintains Regeneron Pharmaceuticals at Neutral, Raises PT from \$89 to \$113

Financial news for REGN dated on 2012-04-26: Regeneron Pharmaceuticals Rises 13% Pre-Market on Solid Earnings Beat

Financial news for REGN dated on 2012-04-26: Regeneron Pharmaceuticals Reports Q1 EPS \$0.37 May Not Compare vs \$-0.24 Est; Revenues \$231.8M vs \$172.62M Est

Financial news for REGN dated on 2012-04-23: UPDATE: Bank of America Raises Regeneron Pharmaceuticals' PO

Financial news for REGN dated on 2012-04-23: Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from \$135 to \$146

Financial news for REGN dated on 2012-04-10: ETFs For Momentum Stocks (FBT, PNQI, HDGE)

Financial news for REGN dated on 2012-04-05: Top Momentum Names to Ride the Rally!

Financial news for REGN dated on 2012-04-05: From Earlier: Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP

Financial news for REGN dated on 2012-03-30: Stocks Close Out Stellar Quarter on High Note; A Look at Top Performers

Financial news for REGN dated on 2012-03-27: Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from \$130 to \$135

Financial news for REGN dated on 2012-03-26: UPDATE: Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody

Financial news for REGN dated on 2012-03-26: J.P. Morgan's Thoughts on Regeneron Pharmaceuticals

Financial news for REGN dated on 2012-03-12: Painkillers Win FDA Panel Backing to Continue Development; Pfizer, JNJ, Regeneron Pain Drugs Should Resume Halted Studies -Bloomberg

Financial news for REGN dated on 2012-03-12: Bank of America Adds Regeneron Pharmaceuticals to US 1 List

Financial news for REGN dated on 2012-03-08: Regeneron and Bayer Announce Approval of EYLEA Injection for the Treatment of Wet Age-Related Macular Degeneration in Australia

Financial news for REGN dated on 2012-02-21: Regeneron Pharmaceuticals Spiking Lower on Negative Comments from Summer Street Research

Financial news for REGN dated on 2012-02-15: Deutsche Bank Comments on Avastin Fake-Out

Financial news for REGN dated on 2012-02-14: UPDATE: Deutsche Bank Raises Target on Regeneron Pharma to \$140

Financial news for REGN dated on 2012-02-14: UPDATE: Bank of America Raises Regeneron Pharmaceuticals PT

Financial news for REGN dated on 2012-02-14: Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from \$105 to \$130

Financial news for REGN dated on 2012-02-13: Regeneron Analyst: More Patients Will Switch From Lucentis to Avastin in 2012. Company Could Sell \$299 Million of Avastin This Year.

Financial news for REGN dated on 2012-02-13: UPDATE: Piper Jaffray Raises Price Target on Regeneron Pharmaceuticals to \$89

Financial news for REGN dated on 2012-02-13: Piper Jaffray Maintains Regeneron Pharmaceuticals at Neutral, Lowers PT from \$81 to \$89

Financial news for REGN dated on 2012-02-13: Piper Jaffray Maintains Regeneron Pharmaceuticals at Neutral, Lowers PT from \$89 to \$81

Financial news for REGN dated on 2012-02-13: Regeneron Pharmaceuticals Hits 52-Week High of \$112.79

Financial news for REGN dated on 2012-02-13: Regeneron Pharmaceuticals up 10.7% Pre-Market on Smaller Than Expected Q4 Loss

Financial news for REGN dated on 2012-02-13: Earnings Roundup

Financial news for REGN dated on 2012-02-13: Benzinga's Top Pre-Market Gainers

Financial news for REGN dated on 2012-02-13: Regeneron Pharmaceuticals Rises 16% on Lower-than-Expected Losses

Financial news for REGN dated on 2012-02-13: Financial Breakfast: Morning News Summary for February 13, 2012

Financial news for REGN dated on 2012-02-13: Regeneron Reports Q4 EPS \$(0.37) vs\$(0.60) Est; Revenues \$123.00M vs \$131.50M Est

Financial news for REGN dated on 2012-02-09: Regeneron Pharmaceuticals Hits 52-Week High of \$102.88

Financial news for REGN dated on 2012-02-08: Regeneron Pharmaceuticals Hits 52-Week High of \$101.99

Financial news for REGN dated on 2012-02-07: Regeneron Pharmaceuticals Hits 52-Week High of \$101.81

Financial news for REGN dated on 2012-02-06: Regeneron Pharmaceuticals Hits 52-Week High of \$97.60

Financial news for REGN dated on 2012-02-06: UPDATE: Piper Jaffray Downgrades Regeneron Pharmaceuticals to Neutral

Financial news for REGN dated on 2012-02-06: Benzinga's Top Downgrades

Financial news for REGN dated on 2012-02-06: Financial Breakfast: Morning News Summary for February 06, 2012

Financial news for REGN dated on 2012-02-06: UPDATE: Jefferies Raises PT to \$1111 on Regeneron Pharmaceuticals

Financial news for REGN dated on 2012-02-06: Piper Jaffray Downgrades Regeneron Pharmaceuticals to Neutral

Financial news for REGN dated on 2012-02-03: Regeneron Pharmaceuticals Hits 52-Week High of \$95.91

Financial news for REGN dated on 2012-02-02: Regeneron Pharmaceuticals Hits 52-Week High of \$93.12

Financial news for REGN dated on 2012-02-01: Regeneron Pharmaceuticals Hits 52-Week High of \$91.78

Financial news for REGN dated on 2012-01-30: Regeneron Pharmaceuticals Hits 52-Week High of \$86.80

Financial news for REGN dated on 2012-01-30: Bank of America Upgrades Regeneron Pharmaceuticals to Buy from Neutral

Financial news for REGN dated on 2012-01-27: Regeneron Pharmaceuticals Hits 52-Week High of \$83.50

Financial news for REGN dated on 2012-01-25: Regeneron Pharmaceuticals Hits 52-Week High of \$80.79

Financial news for REGN dated on 2012-01-19: Regeneron Pharmaceuticals Hits 52-Week High of \$79.98

Financial news for REGN dated on 2012-01-17: Roth Capital Downgrades Regeneron Pharma to Neutral

Financial news for REGN dated on 2012-01-12: Regeneron Pharmaceuticals Hits 52-Week High of \$79.91

Financial news for REGN dated on 2012-01-10: Benzinga's M&A Chatter for Tuesday January 10, 2012

Financial news for REGN dated on 2012-01-10: Regeneron CEO Schleifer: 'We're Excited About the Prospects We've been Working on with Sanofi'

Financial news for REGN dated on 2012-01-10: Regeneron CEO Schleifer: 'Our Bird in the Hand is Eylea'

Financial news for REGN dated on 2012-01-10: Regeneron CEO Schleifer: 'We Try to Develop Products Both Patients and Doctors Will Like'

Financial news for REGN dated on 2012-01-10: Jim Cramer Interviews CEO Dr. Leonard S. Schleifer of Regeneron Pharmaceuticals on Mad Money

Financial news for REGN dated on 2012-01-10: PREVIEW: Jim Cramer to Interview CEO of Regeneron Pharmaceuticals on Mad Money

Financial news for REGN dated on 2012-01-10: UPDATE: Deutsche Bank Maintains Buy, Raises PT to \$80 on Regeneron

Financial news for REGN dated on 2012-01-10: Jefferies Maintains Buy, \$75 PT on Regeneron

Financial news for REGN dated on 2012-01-09: Just What The Doctor Ordered: 4 ETFs For Biotech M&A

Financial news for REGN dated on 2012-01-06: End-of-Day Market Summary for January 6, 2012

Financial news for REGN dated on 2012-01-06: UPDATE: Jefferies & Company Upgrades Regeneron Pharmaceuticals to Buy

Financial news for REGN dated on 2012-01-06: Benzinga's Volume Gainers

Financial news for REGN dated on 2012-01-06: Jefferies Upgrades Regeneron Pharmaceuticals to Buy

Financial news for REGN dated on 2012-01-03: Piper Jaffray Reiterates Overweight, \$83 PT On Regeneron

Financial news for REGN dated on 2012-01-03: A Peek Into The Market Before The Trading Starts

Financial news for REGN dated on 2012-01-03: Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA injection

Financial news for REGN dated on 2012-01-02: Regeneron to Host Conference Call on January 3 at 8:30am EST to Discuss Ongoing Patent Litigation

Financial news for REGN dated on 2011-12-21: Regeneron Informed by Sanofi that on December 19, 2011, Sanofi Voluntarily Withdrew Biologics License Application Submitted to the US FDA for Marketing Approval of ZALTRAP

Financial news for REGN dated on 2011-12-21: Regeneron Says Sanofi Withdrew, Plans to Resubmit Zaltrap BLA

Financial news for REGN dated on 2011-12-16: Regeneron Pharmaceuticals Spiking Lower

on Heavy Volume

Financial news for REGN dated on 2011-12-05: Jefferies Reiterates Hold, \$66 PT On Regeneron

Financial news for REGN dated on 2011-12-05: Brean Murray Lowers PT on Regeneron Pharma to \$67

Financial news for REGN dated on 2011-11-28: Financial Breakfast: Morning News Summary for November 28, 2011

Financial news for REGN dated on 2011-11-28: Regeneron and Bayer Initiate Phase 3 Clinical Program for the Treatment of Wet Age-Related Macular Degeneration in China

Financial news for REGN dated on 2011-11-22: Regeneron Receives FDA Approval; Begins to Eye Bright Future

Financial news for REGN dated on 2011-11-21: End-of-Day Market Summary for November 21, 2011

Financial news for REGN dated on 2011-11-21: Regeneron CEO: Bayer and Regeneron will Split Eylea Profits Outside US

Financial news for REGN dated on 2011-11-21: Regeneron CEO Talking on CNBC

Financial news for REGN dated on 2011-11-21: Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors

Financial news for REGN dated on 2011-11-21: Jefferies Maintains Hold, \$66 PT on Regeneron Pharma

Financial news for REGN dated on 2011-11-21: UPDATE: Bank of America Downgrades Rating to Neutral on Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-11-21: Financial Breakfast: Morning News Summary for November 21, 2011

Financial news for REGN dated on 2011-11-21: UPDATE: Piper Jaffray Raises PT to \$83 on Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-11-21: Bank of America Upgrades Regeneron Pharma to Neutral, PO Raised to \$64

Financial news for REGN dated on 2011-11-21: Piper Jaffray Raises PT on Regeneron Pharmaceuticals to \$83

Financial news for REGN dated on 2011-11-18: Regeneron Announces FDA Approval of EYLEA Injection for Treatment of Wet Age-Related Macular Degeneration

Financial news for REGN dated on 2011-11-18: Regeneron Pharmaceuticals Halted; Announces FDA Approval of EYLEA

Financial news for REGN dated on 2011-11-15: Bank of America Maintains Underperform Rating, \$62 PT on Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-11-14: Stifel Nicolaus Maintains Hold on Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-11-14: Deutsche Bank Maintains Buy Rating and \$67 PT on Regeneron Pharma

Financial news for REGN dated on 2011-11-14: Deutsche Bank Maintains Buy Rating and \$67 PT on Regeneron Pharma

Financial news for REGN dated on 2011-11-10: Hearing Roth Capital Upgrades Regeneron Pharmaceuticals from Hold to Buy

Financial news for REGN dated on 2011-11-07: Deutsche Bank Maintains Buy Rating and \$67 PT on Regeneron Pharma

Financial news for REGN dated on 2011-11-04: FDA Inspectors Find Manufacturing Issues at Roche Avastin Plant

Financial news for REGN dated on 2011-11-04: FDA Inspectors Found Manufacturing Issues at Roche Avastin Plant -Bloomberg

Financial news for REGN dated on 2011-10-27: Regeneron Pharmaceuticals Announces Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting

Financial news for REGN dated on 2011-10-27: Regeneron Pharmaceuticals Reports Q3 EPS \$(0.68) vs \$(0.76) Est; Revenues \$102.8M vs \$115.60M Est

Financial news for REGN dated on 2011-10-18: Hearing Negative Comments on Regeneron by Deal Reporter

Financial news for REGN dated on 2011-10-18: Regeneron Pharmaceuticals Announces Pricing of Offering of \$400M Convertible Senior Notes due October 1, 2016

Financial news for REGN dated on 2011-10-17: Regeneron Pharmaceuticals Announces Proposed Offering of \$400M Convertible Senior Notes due 2016

Financial news for REGN dated on 2011-10-13: Deutsche Bank Maintains Buy Rating and \$67 PT on Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-10-12: UPDATE: Less Costly Avastin May Be Rewarded by U.S. Govt for Wet AMD -Bloomberg

Financial news for REGN dated on 2011-10-12: Regeneron Spiking Lower

Financial news for REGN dated on 2011-10-05: Regeneron Shares Falling On Competitor Concerns

Financial news for REGN dated on 2011-10-05: Regeneron Shares Drop, Novartis Lowers Price of Lucentis by 30%

Financial news for REGN dated on 2011-10-04: J.P. Morgan Initiates Coverage on Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-10-04: JP Morgan Initiates Regeneron Pharmaceuticals at Neutral, \$60 PT

Financial news for REGN dated on 2011-09-26: Piper Jaffray Overweight on Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-09-26: Piper Jaffray Raises PT on Regeneron Pharmaceuticals to \$73

Financial news for REGN dated on 2011-09-23: Regeneron Announces ZALTRAP(r) Clinical Presentation at European Multidisciplinary Cancer Congress

Financial news for REGN dated on 2011-09-21: Afternoon Gainers; HP Up Over 8%

Financial news for REGN dated on 2011-09-21: Regeneron Pharmaceuticals Soars On Avastin Announcement

Financial news for REGN dated on 2011-09-21: Option Alert: Regeneron October 80 Call Rises 600% on News

Financial news for REGN dated on 2011-09-21: Regeneron Pharmaceuticals Resumes Trading

Financial news for REGN dated on 2011-09-21: Regeneron Pharmaceuticals Halted Again, Circuit Breaker

Financial news for REGN dated on 2011-09-21: Regeneron Pharmaceuticals Resumes Trading

Financial news for REGN dated on 2011-09-21: VA Drops Roche's Avastin for Eye Disease Citing Infection Risks

Financial news for REGN dated on 2011-09-21: Regeneron Pharmaceuticals Halted, Single-Stock Circuit Breaker

Financial news for REGN dated on 2011-09-21: Regeneron Pharmaceuticals Spiking Higher on Heavy Volume

Financial news for REGN dated on 2011-09-20: Jefferies Initiates Coverage on Regeneron Pharmaceuticals with Hold Rating

Financial news for REGN dated on 2011-09-20: Jefferies Initiates Regeneron Pharmaceuticals at Hold, \$66 PT

Financial news for REGN dated on 2011-09-19: Midday Gainers; Pandora up Nearly 7%

Financial news for REGN dated on 2011-09-09: Midday Movers; Deutsche Bank Down 8%

Financial news for REGN dated on 2011-09-09: Bank of America Merrill Lynch Downgrades

Regeneron

Financial news for REGN dated on 2011-09-09: Bank of America Downgrades Regeneron Pharmaceuticals To Underperform, Raises PO To \$62

Financial news for REGN dated on 2011-09-09: Hearing Leerink Swann and Bank of America Merrill Lynch Downgraded Regeneron

Financial news for REGN dated on 2011-09-08: Breaking the Trend: Stocks Hitting 52-Week Highs Despite Today's Selloff

Financial news for REGN dated on 2011-09-06: Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary

Financial news for REGN dated on 2011-09-02: Regeneron Pharmaceuticals Rises 14% on Positive Seeking Alpha Blog Post Yesterday

Financial news for REGN dated on 2011-08-26: UPDATE: Citi Downgrades Regeneron To Hold

Financial news for REGN dated on 2011-08-26: Benzinga's Top Downgrades

Financial news for REGN dated on 2011-08-26: Citigroup Downgrades Regeneron Pharmaceuticals To Hold, Lowers PT To \$60

Financial news for REGN dated on 2011-08-18: Regeneron Blindsided By PDFUA Delay

Financial news for REGN dated on 2011-08-18: Bank of America Merrill Lynch Maintains Neutral on Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-08-16: Regeneron Announces Review of Biologics License Application for EYLEA; Says Review Extended by 3 Months by FDA

Financial news for REGN dated on 2011-08-15: Piper Jaffray Reiterates Overweight Rating On Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-07-25: Monday's Put/Call Ratio Leaders

Financial news for REGN dated on 2011-07-21: Regeneron Pharma Spiking Lower on Heavy Volume

Financial news for REGN dated on 2011-07-21: Fifteen Health Care ETFs Trading Near 52-Week Highs

Financial news for REGN dated on 2011-07-20: Biotech/Pharma Stocks Investor News Alert

Financial news for REGN dated on 2011-07-19: Deutsche Bank Comments on Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-07-13: Twelve Health Care ETFs Trading Near 52-Week Highs

Financial news for REGN dated on 2011-07-13: Piper Jaffray Reiterates Overweight and PT of \$62 on Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-07-12: Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis

Financial news for REGN dated on 2011-07-07: Catalysts Abound For Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-07-07: Phase 3 Trial of ZALTRAP in Advanced Prostate Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee

Financial news for REGN dated on 2011-06-28: Money Flowing Into Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-06-20: Piper Jaffray Reiterates Overweight Rating On Regeneron

Financial news for REGN dated on 2011-06-17: Regeneron Showing Volatile Movement After Trading Resumption, Trading Lower After Winning Panel's Backing

Financial news for REGN dated on 2011-06-17: Regeneron Pharmaceuticals Up Slightly Despite FDA Approval

Financial news for REGN dated on 2011-06-17: PREVIEW: Regeneron to Resume Trading at

2.20 pm EST

Financial news for REGN dated on 2011-06-17: Regeneron Announces EYLEA Receives Unanimous Recommendation for Approval for Treatment of Wet AMD from FDA Advisory Committee

Financial news for REGN dated on 2011-06-17: FDA Advisory Panel Backs Regeneron's Eye Treatment 10-0

Financial news for REGN dated on 2011-06-17: Regeneron Halted Ahead Of FDA

Financial news for REGN dated on 2011-06-17: Trading in Regeneron Common Stock Halted for FDA Review

Financial news for REGN dated on 2011-06-15: Top Percentage Gainers and Losers as of 2pm 06/15/11

Financial news for REGN dated on 2011-06-15: Benzinga's Volume Movers

Financial news for REGN dated on 2011-06-15: UPDATE: Regeneron's Drug was not Superior to the Roche Drug at Any Dose Level

Financial news for REGN dated on 2011-06-15: UPDATE: Regeneron Eye Drug Meets FDA's Effectiveness Goals; Raises No Major Safety Concerns

Financial news for REGN dated on 2011-06-14: Regeneron Pharma Eye Drug Faces FDA Panel Review Friday -Dow Jones

Financial news for REGN dated on 2011-06-13: Piper Jaffray Reiterates Overweight on Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-06-10: Bank of America Merrill Lynch Maintains Buy on Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-06-09: Puts Purchased on Regeneron Pharmaceuticals

Financial news for REGN dated on 2011-05-31: Regeneron Pharmaceuticals Spiking

Financial news for REGN dated on 2011-05-23: Regeneron Pharmaceuticals Announces FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration

Financial news for REGN dated on 2011-05-23: Regeneron's Aflibercept Eye Solution To Face FDA Advisory Panel -Bloomberg

Financial news for REGN dated on 2011-05-02: CEOWORLD TOP 5 higher priced Biotechnology stocks picks- BIIB, CBST, MYGN, REGN and ITMN

Financial news for REGN dated on 2011-05-02: Piper Jaffray Reiterates Overweight on Regeneron Pharmaceuticals (REGN)

Financial news for REGN dated on 2011-04-28: Short-Term Traders Should Check Out Regeneron (REGN)

Financial news for REGN dated on 2011-04-28: Stocks we are watching on 4/28- AMZN, LVLTL, NFLX, BIDU, ORCL, YRCW, AMD, GS, POT, FCX, SNDK, IRE, AIB, CIGX, CTIC, AKAM, WFMI

Financial news for REGN dated on 2011-04-28: Brean Murray Raises REGN Target From \$67 To \$78

Financial news for REGN dated on 2011-04-28: CEOWORLD Top 10 most active stocks on 28 April- CEG, SBUX, NTRI, AKAM, REGN, CXTS, EQIX, ALL, BIDU, LOOP

Financial news for REGN dated on 2011-04-27: Top Percentage Gainers and Losers as of 2pm 4/27/11 (RLOC, REGN, SIMG, SHOR, MOBI, MIPS, SFN, SCEI, BRCM, MRCY, GOOG)

Financial news for REGN dated on 2011-04-27: Regeneron Pharmaceuticals Soars 33% (REGN)

Financial news for REGN dated on 2011-04-27: Piper Jaffray Raises PT To \$62 On REGN

Financial news for REGN dated on 2011-04-27: Piper Jaffray Raises PT On Regeneron Pharmaceuticals To \$62

Financial news for REGN dated on 2011-04-26: Regeneron Pharmaceuticals Jumps 14% After Halt (REGN)

Financial news for REGN dated on 2011-04-26: Sanofi-aventis and Regeneron Report Positive Phase III Results With ZALTRAP in Second-line Metastatic Colorectal Cancer

Financial news for REGN dated on 2011-04-26: Sanofi-aventis and Regeneron Report Positive Phase III Results With ZALTRAP(tm) (SNY, REGN)

Financial news for REGN dated on 2011-04-21: Options Brief: Regeneron Pharmaceuticals, Inc. (REGN)

Financial news for REGN dated on 2011-04-18: Regeneron Pharmaceuticals Announces FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration

Financial news for REGN dated on 2011-04-13: UPDATE: Deutsche Bank Initiates Regeneron Pharma at Buy (REGN)

Financial news for REGN dated on 2011-04-13: Deutsche Bank Initiates Regeneron Pharma At Buy, \$67 PT

Financial news for REGN dated on 2011-04-08: Piper Jaffray Overweight On Regeneron Pharmaceuticals (REGN)

Financial news for REGN dated on 2011-04-07: Roth Capital Downs REGN To Neutral

Financial news for REGN dated on 2011-03-24: Calls Purchased on Regeneron Pharmaceuticals (REGN)

Financial news for REGN dated on 2011-03-11: Piper Jaffray Trims Regeneron Pharmaceuticals PT To \$48 (REGN)

Financial news for REGN dated on 2011-03-10: Regeneron Pharms Reports Top-Line Phase III Results (REGN)

Financial news for REGN dated on 2011-02-24: RBC Capital Ups REGN To Outperform

Financial news for REGN dated on 2011-02-22: Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment

Financial news for REGN dated on 2011-02-14: Benzinga's Volume Movers (KVHI, REGN, ARTC, AAWW)

Financial news for REGN dated on 2011-02-14: NASDAQ Stocks Hitting 52-Week Highs (MWIV, REGN, ZOLT, KAMN)

Financial news for REGN dated on 2011-02-14: Piper Jaffray Overweight On Regeneron Pharmaceuticals (REGN)

Financial news for REGN dated on 2011-02-14: Piper Jaffray Raises PT On Regeneron Pharmaceuticals To \$46

Financial news for REGN dated on 2011-02-07: Piper Jaffray Reiterates OW Rating, \$40 PT On REGN

Financial news for REGN dated on 2011-01-18: REGN's Pipeline Advances - Analyst Blog

Financial news for REGN dated on 2011-01-18: REGN's Pipeline Advances - Analyst Blog

Financial news for REGN dated on 2011-01-07: Ardea's Promising Gout Candidate - Analyst Blog

Financial news for REGN dated on 2011-01-07: Ardea's Promising Gout Candidate - Analyst Blog

Financial news for REGN dated on 2011-01-05: Piper Jaffray's Favorite Antibody Plays (SGEN, MITI, REGN)

Financial news for REGN dated on 2010-12-28: Jolt for Regeneron's Pipeline - Analyst Blog

Financial news for REGN dated on 2010-12-28: Jolt for Regeneron's Pipeline - Analyst Blog

Financial news for REGN dated on 2010-12-20: Sanofi Expands Oncology Pipeline - Analyst Blog

Financial news for REGN dated on 2010-12-20: Sanofi Expands Oncology Pipeline - Analyst Blog

Financial news for REGN dated on 2010-11-29: Neutral on Regeneron - Analyst Blog

Financial news for REGN dated on 2010-11-29: Neutral on Regeneron - Analyst Blog

Financial news for REGN dated on 2010-11-23: Regeneron Pipeline Progresses - Analyst Blog

Financial news for REGN dated on 2010-11-23: RBC Capital Mkts. Increases Price Target (REGN, NOC, HPQ)

Financial news for REGN dated on 2010-11-23: Regeneron Pipeline Progresses - Analyst Blog

Financial news for REGN dated on 2010-11-22: Benzinga's Volume Movers (REGN, GMCR, CTRN, CRUS)

Financial news for REGN dated on 2010-11-22: Regeneron Pharmaceuticals Up 15% (REGN)

Financial news for REGN dated on 2010-11-04: Loss at REGN Wider than Expected - Analyst Blog

Financial news for REGN dated on 2010-11-02: Calls Purchased on Regeneron Pharmaceuticals (REGN)

Financial news for REGN dated on 2010-10-13: Regeneron Announces Closing of Underwritten Offering of Common Stock; Raises \$175.1M

Financial news for REGN dated on 2010-10-08: Regeneron Increases Size of Public Offering of Common Stock

Financial news for REGN dated on 2010-10-06: Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares

Financial news for REGN dated on 2010-09-22: Buy REGN Ahead Of VEGF Trap-Eye Data In December

Financial news for REGN dated on 2010-09-09: Good News for Regeneron - Analyst Blog

Financial news for REGN dated on 2010-09-09: Piper Jaffray Sees Sharp Upside In Regeneron (REGN)

Financial news for REGN dated on 2010-08-18: 2H:10 Milestones In Drug Discovery (ARNA, VRTX, REGN, EXEL)

Financial news for REGN dated on 2010-08-17: Ardea remains Neutral - Analyst Blog

Financial news for REGN dated on 2010-08-09: Q2 Loss Widens at Ardea - Analyst Blog

Financial news for REGN dated on 2010-07-30: REGN's Loss Narrower than Expected - Analyst Blog

Financial news for REGN dated on 2010-06-21: Put Volume Grows on Regeneron Pharma (REGN)

Financial news for REGN dated on 2010-05-12: Regeneron (REGN) Closes 8.70% Higher

Financial news for REGN dated on 2010-05-12: Market Update - IBM (NYSE: IBM), Wal-Mart (NYSE: WMT), Sybase (NYSE: SY), Regeneron (NASDAQ: REGN)

Financial news for REGN dated on 2010-04-08: PowerShares Small Cap Sector ETFs Hit the Tape

Financial news for REGN dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?